EP1532150B1 - Nouveaux derives de purine, leur procede de production et leur utilisation en tant que medicament - Google Patents
Nouveaux derives de purine, leur procede de production et leur utilisation en tant que medicament Download PDFInfo
- Publication number
- EP1532150B1 EP1532150B1 EP03792343A EP03792343A EP1532150B1 EP 1532150 B1 EP1532150 B1 EP 1532150B1 EP 03792343 A EP03792343 A EP 03792343A EP 03792343 A EP03792343 A EP 03792343A EP 1532150 B1 EP1532150 B1 EP 1532150B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- alkyl
- amino
- piperidin
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title claims abstract description 4
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title claims abstract 6
- 239000003814 drug Substances 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 97
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 150000007522 mineralic acids Chemical class 0.000 claims abstract description 5
- -1 pyrrolidin-1-ylcarbonyl Chemical group 0.000 claims description 436
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 107
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 77
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 43
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 42
- 125000003277 amino group Chemical group 0.000 claims description 38
- 125000001624 naphthyl group Chemical group 0.000 claims description 37
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 36
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims description 32
- 125000004432 carbon atom Chemical group C* 0.000 claims description 30
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 23
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 21
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 21
- 229910052731 fluorine Inorganic materials 0.000 claims description 21
- 239000011737 fluorine Substances 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 20
- 229910052801 chlorine Inorganic materials 0.000 claims description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 239000000460 chlorine Substances 0.000 claims description 18
- 125000006563 (C1-3) alkylaminocarbonyl group Chemical group 0.000 claims description 17
- 125000006576 di-(C1-C3-alkyl)-aminocarbonyl group Chemical group 0.000 claims description 17
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 17
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 15
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 13
- 125000002541 furyl group Chemical group 0.000 claims description 13
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 125000001544 thienyl group Chemical group 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 8
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 7
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 claims description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 5
- RNRPZHYVLILOGM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-methyl-7-(3-methylbut-2-enyl)-1-(naphthalen-1-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(C)N(CC=3C4=CC=CC=C4C=CC=3)C(=O)C=2N(CC=C(C)C)C=1N1CCCC(N)C1 RNRPZHYVLILOGM-UHFFFAOYSA-N 0.000 claims description 5
- PNOSIUFCRSQTOB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(3-methylbut-2-enyl)-1-(naphthalen-1-ylmethyl)purin-6-one Chemical compound N=1C=2N=CN(CC=3C4=CC=CC=C4C=CC=3)C(=O)C=2N(CC=C(C)C)C=1N1CCCC(N)C1 PNOSIUFCRSQTOB-UHFFFAOYSA-N 0.000 claims description 5
- KYDFKPMXUILEAA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-phenacylpurin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC=CC=1)C=N2 KYDFKPMXUILEAA-UHFFFAOYSA-N 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 150000001721 carbon Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 5
- 150000003212 purines Chemical class 0.000 claims description 5
- 125000006599 (C1-C3) alkylaminocarbonylamino group Chemical group 0.000 claims description 4
- 125000006602 (C1-C3) alkylsulfonylamino group Chemical group 0.000 claims description 4
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical group O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 4
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- MLEOPWDMSPGAJV-UHFFFAOYSA-N 2-amino-8-(3-aminopiperidin-1-yl)-7-benzyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N)=NC=2N=C1N1CCCC(N)C1 MLEOPWDMSPGAJV-UHFFFAOYSA-N 0.000 claims description 3
- LNUIDEMUMXLMOV-UHFFFAOYSA-N 7-[(4-fluorophenyl)methyl]-8-(piperidin-4-ylmethyl)-3h-purin-6-one Chemical compound C=1C=C(F)C=CC=1CN1C=2C(O)=NC=NC=2N=C1CC1CCNCC1 LNUIDEMUMXLMOV-UHFFFAOYSA-N 0.000 claims description 3
- VEJJMWUFHYIMLI-UHFFFAOYSA-N 7-[(4-fluorophenyl)methyl]-8-[(1-methylpiperidin-4-yl)methyl]-3h-purin-6-one Chemical compound C1CN(C)CCC1CC(N1CC=2C=CC(F)=CC=2)=NC2=C1C(=O)NC=N2 VEJJMWUFHYIMLI-UHFFFAOYSA-N 0.000 claims description 3
- AHRPGBIQGOKCEJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-[(4-methoxynaphthalen-1-yl)methyl]-7-(3-methylbut-2-enyl)purin-6-one Chemical compound C12=CC=CC=C2C(OC)=CC=C1CN(C(C=1N2CC=C(C)C)=O)C=NC=1N=C2N1CCCC(N)C1 AHRPGBIQGOKCEJ-UHFFFAOYSA-N 0.000 claims description 3
- KXZCVZCPENDTBZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-7-(3-methylbut-2-enyl)-2-(2-phenylethyl)purin-6-one Chemical compound CN1C(=O)C=2N(CC=C(C)C)C(N3CC(N)CCC3)=NC=2N=C1CCC1=CC=CC=C1 KXZCVZCPENDTBZ-UHFFFAOYSA-N 0.000 claims description 3
- ZSJQMFQPGXOVJF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(3-methylbut-2-enyl)purin-6-one Chemical compound CN1C(=O)C=2N(CC=C(C)C)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 ZSJQMFQPGXOVJF-UHFFFAOYSA-N 0.000 claims description 3
- IHELHBZSOOCKJI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1,2-dimethylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C)=NC=2N=C1N1CCCC(N)C1 IHELHBZSOOCKJI-UHFFFAOYSA-N 0.000 claims description 3
- VLBIYRJVPOZOET-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCC1=CC=CC=C1 VLBIYRJVPOZOET-UHFFFAOYSA-N 0.000 claims description 3
- FWURZHRNHYFNNY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(methylamino)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NC)=NC=2N=C1N1CCCC(N)C1 FWURZHRNHYFNNY-UHFFFAOYSA-N 0.000 claims description 3
- UUBYQARNFLJUIF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(propan-2-ylamino)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NC(C)C)=NC=2N=C1N1CCCC(N)C1 UUBYQARNFLJUIF-UHFFFAOYSA-N 0.000 claims description 3
- LIQQAKDINRZTHI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-piperidin-1-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCCCC3)=NC=2N=C1N1CCCC(N)C1 LIQQAKDINRZTHI-UHFFFAOYSA-N 0.000 claims description 3
- KHCNZQNITHNYGN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C=NC=2N=C1N1CCCC(N)C1 KHCNZQNITHNYGN-UHFFFAOYSA-N 0.000 claims description 3
- KXEVVOQPEOZACT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 KXEVVOQPEOZACT-UHFFFAOYSA-N 0.000 claims description 3
- DSUCMFGGJJWNGH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclohexylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1CCCCC1 DSUCMFGGJJWNGH-UHFFFAOYSA-N 0.000 claims description 3
- MUJRWAFVKMBLQJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(dimethylamino)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N(C)C)=NC=2N=C1N1CCCC(N)C1 MUJRWAFVKMBLQJ-UHFFFAOYSA-N 0.000 claims description 3
- WRFSHVCQKQZCJT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(4-fluorophenyl)methylamino]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(F)C=C1 WRFSHVCQKQZCJT-UHFFFAOYSA-N 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 125000004610 3,4-dihydro-4-oxo-quinazolinyl group Chemical group O=C1NC(=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 2
- 125000005184 naphthylamino group Chemical group C1(=CC=CC2=CC=CC=C12)N* 0.000 claims description 2
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- SYGWYBOJXOGMRU-UHFFFAOYSA-N chembl233051 Chemical compound C1=CC=C2C3=CC(C(N(CCN(C)C)C4=O)=O)=C5C4=CC=CC5=C3SC2=C1 SYGWYBOJXOGMRU-UHFFFAOYSA-N 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 239000000651 prodrug Substances 0.000 abstract description 5
- 229940002612 prodrug Drugs 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 150000007529 inorganic bases Chemical class 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 4
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 264
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 252
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 104
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 68
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 50
- 239000000741 silica gel Substances 0.000 description 43
- 229910002027 silica gel Inorganic materials 0.000 description 43
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000013543 active substance Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 20
- 125000003545 alkoxy group Chemical group 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 238000001819 mass spectrum Methods 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 4
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 125000006595 (C1-C3) alkylsulfinyl group Chemical group 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 3
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- WUOQXNWMYLFAHT-UHFFFAOYSA-N tert-butyl n-piperidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCCNC1 WUOQXNWMYLFAHT-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 2
- IVBVTJRJXOWINB-UHFFFAOYSA-N (4-methoxynaphthalen-1-yl)methanamine Chemical compound C1=CC=C2C(OC)=CC=C(CN)C2=C1 IVBVTJRJXOWINB-UHFFFAOYSA-N 0.000 description 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 2
- FLAJOCQODOSXOM-UHFFFAOYSA-N 1-[2-(2-aminophenyl)-2-oxoethyl]-8-(3-aminopiperidin-1-yl)-7-benzylpurin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C(=CC=CC=1)N)C=N2 FLAJOCQODOSXOM-UHFFFAOYSA-N 0.000 description 2
- KRJREJJSSOFZFI-UHFFFAOYSA-N 2-(2-aminoethylamino)-8-(3-aminopiperidin-1-yl)-7-benzyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCN)=NC=2N=C1N1CCCC(N)C1 KRJREJJSSOFZFI-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GZUSRPVTBVKCCC-UHFFFAOYSA-N 2-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenoxy]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)COC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 GZUSRPVTBVKCCC-UHFFFAOYSA-N 0.000 description 2
- RRKJMBVHFCFUKA-UHFFFAOYSA-N 2-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenoxy]-n-ethylacetamide Chemical compound CCNC(=O)COC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 RRKJMBVHFCFUKA-UHFFFAOYSA-N 0.000 description 2
- ZXOHWBJWDQRNQU-UHFFFAOYSA-N 2-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenoxy]-n-methylacetamide Chemical compound CNC(=O)COC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 ZXOHWBJWDQRNQU-UHFFFAOYSA-N 0.000 description 2
- GQJSLRBSMGEGHR-UHFFFAOYSA-N 2-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenoxy]acetamide Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C(=CC=CC=1)OCC(N)=O)C=N2 GQJSLRBSMGEGHR-UHFFFAOYSA-N 0.000 description 2
- GTQOPHWORUTDBG-UHFFFAOYSA-N 2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]ethyl]benzamide Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1C(N)=O GTQOPHWORUTDBG-UHFFFAOYSA-N 0.000 description 2
- JXZLJXRJKMGQTJ-UHFFFAOYSA-N 2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]ethyl]benzonitrile Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1C#N JXZLJXRJKMGQTJ-UHFFFAOYSA-N 0.000 description 2
- JLNZVAJNRRUVMK-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-1-methyl-6-oxo-2-(2-phenylethyl)purin-7-yl]methyl]benzonitrile Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C(=CC=CC=3)C#N)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 JLNZVAJNRRUVMK-UHFFFAOYSA-N 0.000 description 2
- ZYHJOGUZHBMFAO-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-6-oxopurin-7-yl]methyl]benzonitrile Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C(=CC=CC=3)C#N)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 ZYHJOGUZHBMFAO-UHFFFAOYSA-N 0.000 description 2
- COTHKKBXRJQJNV-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]-n,n-dimethylacetamide Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(=O)N(C)C)=NC=2N=C1N1CCCC(N)C1 COTHKKBXRJQJNV-UHFFFAOYSA-N 0.000 description 2
- MXVVJUKEJMHBOT-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]-n-ethylacetamide Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(=O)NCC)=NC=2N=C1N1CCCC(N)C1 MXVVJUKEJMHBOT-UHFFFAOYSA-N 0.000 description 2
- ZGVPJPKVGYSXHV-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]acetamide Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(N)=O)=NC=2N=C1N1CCCC(N)C1 ZGVPJPKVGYSXHV-UHFFFAOYSA-N 0.000 description 2
- IQILBLAIIVGKOY-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]acetic acid Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(O)=O)=NC=2N=C1N1CCCC(N)C1 IQILBLAIIVGKOY-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- MYRFQYMNEHTQDJ-UHFFFAOYSA-N 2-amino-8-(3-aminopiperidin-1-yl)-7-benzyl-1-methylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N)=NC=2N=C1N1CCCC(N)C1 MYRFQYMNEHTQDJ-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- IZYTVPWMGQQFJU-UHFFFAOYSA-N 3-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]propanenitrile Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCC#N)=NC=2N=C1N1CCCC(N)C1 IZYTVPWMGQQFJU-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- WJTIRCVXQBFGHY-UHFFFAOYSA-N 7-benzyl-1-methyl-2-(2-phenylethyl)-8-piperazin-1-ylpurin-6-one Chemical compound N=1C=2N=C(N3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 WJTIRCVXQBFGHY-UHFFFAOYSA-N 0.000 description 2
- KOPVSTAUTXJATB-UHFFFAOYSA-N 7-benzyl-1-methyl-2-(2-phenylethyl)-8-piperidin-3-ylpurin-6-one Chemical compound N=1C=2N=C(C3CNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 KOPVSTAUTXJATB-UHFFFAOYSA-N 0.000 description 2
- JLIAMELIHQIZQK-UHFFFAOYSA-N 7-benzyl-1-methyl-2-(2-phenylethyl)-8-piperidin-4-ylpurin-6-one Chemical compound N=1C=2N=C(C3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 JLIAMELIHQIZQK-UHFFFAOYSA-N 0.000 description 2
- DPUNDSGILOVWQP-UHFFFAOYSA-N 7-benzyl-2-(benzylamino)-1-methyl-8-piperazin-1-ylpurin-6-one Chemical compound N=1C=2N=C(N3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 DPUNDSGILOVWQP-UHFFFAOYSA-N 0.000 description 2
- XXJGHTUNTCKDEW-UHFFFAOYSA-N 7-benzyl-2-(benzylamino)-1-methyl-8-piperidin-3-ylpurin-6-one Chemical compound N=1C=2N=C(C3CNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 XXJGHTUNTCKDEW-UHFFFAOYSA-N 0.000 description 2
- FQWIXFCSJOZTTO-UHFFFAOYSA-N 7-benzyl-2-(benzylamino)-1-methyl-8-piperidin-4-ylpurin-6-one Chemical compound N=1C=2N=C(C3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 FQWIXFCSJOZTTO-UHFFFAOYSA-N 0.000 description 2
- OOIHIBBRPDINRI-UHFFFAOYSA-N 7-benzyl-2-(benzylamino)-8-(1,4-diazepan-1-yl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CCNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 OOIHIBBRPDINRI-UHFFFAOYSA-N 0.000 description 2
- NPRVPCMRNIOMMY-UHFFFAOYSA-N 7-benzyl-8-(1,4-diazepan-1-yl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CCNCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 NPRVPCMRNIOMMY-UHFFFAOYSA-N 0.000 description 2
- KSMIBFQFZLRYPE-UHFFFAOYSA-N 8-(2-aminoethylamino)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(NCCN)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 KSMIBFQFZLRYPE-UHFFFAOYSA-N 0.000 description 2
- HBMJKFUFEOTDEH-UHFFFAOYSA-N 8-(3-aminoazepan-1-yl)-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 HBMJKFUFEOTDEH-UHFFFAOYSA-N 0.000 description 2
- IHBSNILKCZIJNC-UHFFFAOYSA-N 8-(3-aminoazepan-1-yl)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 IHBSNILKCZIJNC-UHFFFAOYSA-N 0.000 description 2
- NKNQXCRHIIZJQP-UHFFFAOYSA-N 8-(3-aminocyclohexyl)-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(C3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 NKNQXCRHIIZJQP-UHFFFAOYSA-N 0.000 description 2
- FJTNFYWQTLWDTR-UHFFFAOYSA-N 8-(3-aminocyclohexyl)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(C3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 FJTNFYWQTLWDTR-UHFFFAOYSA-N 0.000 description 2
- MKYVZONQQIQRRI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1,7-dibenzyl-2-methylsulfanylpurin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(CC=3C=CC=CC=3)C(SC)=NC=2N=C1N1CCCC(N)C1 MKYVZONQQIQRRI-UHFFFAOYSA-N 0.000 description 2
- UFPRKXYSXDXGAL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-benzyl-2-methyl-7-(3-methylbut-2-enyl)purin-6-one Chemical compound O=C1C=2N(CC=C(C)C)C(N3CC(N)CCC3)=NC=2N=C(C)N1CC1=CC=CC=C1 UFPRKXYSXDXGAL-UHFFFAOYSA-N 0.000 description 2
- TXZHFHVENMXHTE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-2-(2-phenylethyl)-7-(pyridin-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3N=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 TXZHFHVENMXHTE-UHFFFAOYSA-N 0.000 description 2
- UMOGJCJKMXWZBE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-2-(2-phenylethyl)-7-(thiophen-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3SC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 UMOGJCJKMXWZBE-UHFFFAOYSA-N 0.000 description 2
- YGXWTVPUDSMXGJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-2-(2-phenylethyl)-7-[[3-(trifluoromethoxy)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(OC(F)(F)F)C=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 YGXWTVPUDSMXGJ-UHFFFAOYSA-N 0.000 description 2
- YTMDEJDMTYLIHM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-2-(2-phenylethyl)-7-[[3-(trifluoromethyl)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(C=CC=3)C(F)(F)F)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 YTMDEJDMTYLIHM-UHFFFAOYSA-N 0.000 description 2
- OZQBTWNPJJPWAA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-7-(3-methylbut-2-enyl)-2-(2-phenylethyl)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC=C(C)C)C(N3CC(N)CCC3)=NC=2N=C1CCC1=CC=CC=C1 OZQBTWNPJJPWAA-UHFFFAOYSA-N 0.000 description 2
- QRPSFKHJZYEAHB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-7-(naphthalen-1-ylmethyl)-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C4=CC=CC=C4C=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 QRPSFKHJZYEAHB-UHFFFAOYSA-N 0.000 description 2
- FLXMKFPTUIVGEM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-1-methyl-7-[(3-methylphenyl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound CC1=CC=CC(CN2C=3C(=O)N(C)C(CCC=4C=CC=CC=4)=NC=3N=C2N2CC(N)CCC2)=C1 FLXMKFPTUIVGEM-UHFFFAOYSA-N 0.000 description 2
- JOCZHILRODVRIF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2,7-dibenzyl-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC=C1 JOCZHILRODVRIF-UHFFFAOYSA-N 0.000 description 2
- IEPSUMUSBIZHQO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(1,3-benzodioxol-5-ylmethylamino)-7-benzyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC=3C=C4OCOC4=CC=3)=NC=2N=C1N1CCCC(N)C1 IEPSUMUSBIZHQO-UHFFFAOYSA-N 0.000 description 2
- ATJMADWEHCXJNC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(3-aminopropylamino)-7-benzyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCCN)=NC=2N=C1N1CCCC(N)C1 ATJMADWEHCXJNC-UHFFFAOYSA-N 0.000 description 2
- DNCWLRTXQXJVRK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(2-methylbut-2-enyl)purin-6-one Chemical compound CN1C(=O)C=2N(CC(C)=CC)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 DNCWLRTXQXJVRK-UHFFFAOYSA-N 0.000 description 2
- BAQZTNVCGOQKAB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(3-methylbut-2-enyl)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC=C(C)C)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 BAQZTNVCGOQKAB-UHFFFAOYSA-N 0.000 description 2
- VEXDKNBPWBQESI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(naphthalen-1-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C4=CC=CC=C4C=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 VEXDKNBPWBQESI-UHFFFAOYSA-N 0.000 description 2
- DMGUQGAHBCENRS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(pyridin-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3N=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 DMGUQGAHBCENRS-UHFFFAOYSA-N 0.000 description 2
- HIJIEWCANFRPDA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-(thiophen-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3SC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 HIJIEWCANFRPDA-UHFFFAOYSA-N 0.000 description 2
- HOKXUPLBAFQSAQ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-[(3-methylphenyl)methyl]purin-6-one Chemical compound CC1=CC=CC(CN2C=3C(=O)N(C)C(NCC=4C=CC=CC=4)=NC=3N=C2N2CC(N)CCC2)=C1 HOKXUPLBAFQSAQ-UHFFFAOYSA-N 0.000 description 2
- LEISEQWHMSDMMB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-[[3-(trifluoromethoxy)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(OC(F)(F)F)C=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 LEISEQWHMSDMMB-UHFFFAOYSA-N 0.000 description 2
- GRJASLTVWZSWOS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-1-methyl-7-[[3-(trifluoromethyl)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(C=CC=3)C(F)(F)F)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 GRJASLTVWZSWOS-UHFFFAOYSA-N 0.000 description 2
- GIEDBTBRUJHKQZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(2,3-dimethylbut-2-enyl)-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC(C)=C(C)C)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 GIEDBTBRUJHKQZ-UHFFFAOYSA-N 0.000 description 2
- BWTKISXNDHYCBF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(3,3-dichloroprop-2-enyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=C(Cl)Cl)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 BWTKISXNDHYCBF-UHFFFAOYSA-N 0.000 description 2
- FTXNKGLVTOYRPO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(3-chloro-4,4,4-trifluorobut-2-enyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=C(Cl)C(F)(F)F)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 FTXNKGLVTOYRPO-UHFFFAOYSA-N 0.000 description 2
- HQHMJOWXKLXPSC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(3-chlorobut-2-enyl)-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC=C(Cl)C)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 HQHMJOWXKLXPSC-UHFFFAOYSA-N 0.000 description 2
- MNLNTHIRGONVJU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(3-chloroprop-2-enyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=CCl)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 MNLNTHIRGONVJU-UHFFFAOYSA-N 0.000 description 2
- VUHZUUQLBBSMSE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(cyclohexen-1-ylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3CCCCC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 VUHZUUQLBBSMSE-UHFFFAOYSA-N 0.000 description 2
- ILFVBNGBYJQYDV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(cyclohexylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC3CCCCC3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 ILFVBNGBYJQYDV-UHFFFAOYSA-N 0.000 description 2
- RATUKNHJSYAEHE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(cyclopenten-1-ylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3CCCC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 RATUKNHJSYAEHE-UHFFFAOYSA-N 0.000 description 2
- RGNZFJLRSHXDNM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-(furan-2-ylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3OC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 RGNZFJLRSHXDNM-UHFFFAOYSA-N 0.000 description 2
- OYPXHQZMQLREQH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[(2-chlorophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C(=CC=CC=3)Cl)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 OYPXHQZMQLREQH-UHFFFAOYSA-N 0.000 description 2
- SHWXAEPYBCGDOZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[(2-methoxyphenyl)methyl]-1-methylpurin-6-one Chemical compound COC1=CC=CC=C1CN1C(C(=O)N(C)C(NCC=2C=CC=CC=2)=N2)=C2N=C1N1CC(N)CCC1 SHWXAEPYBCGDOZ-UHFFFAOYSA-N 0.000 description 2
- JEZDREHKVMZBOZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[(3,4-difluorophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(F)C(F)=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 JEZDREHKVMZBOZ-UHFFFAOYSA-N 0.000 description 2
- OJDIRPFGMHQCCE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[(3-bromophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(Br)C=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 OJDIRPFGMHQCCE-UHFFFAOYSA-N 0.000 description 2
- OXUNPAXYXYVVRS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[(4-fluorophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC(F)=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 OXUNPAXYXYVVRS-UHFFFAOYSA-N 0.000 description 2
- BYGDUKIAVIQCLN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-[[3-(difluoromethoxy)phenyl]methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(OC(F)F)C=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 BYGDUKIAVIQCLN-UHFFFAOYSA-N 0.000 description 2
- KQKPBMRCKYGONU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-but-2-enyl-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC=CC)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 KQKPBMRCKYGONU-UHFFFAOYSA-N 0.000 description 2
- RTDVHLKINWMRDM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-anilino-7-benzyl-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1=CC=CC=C1 RTDVHLKINWMRDM-UHFFFAOYSA-N 0.000 description 2
- AEJXFOVWNYZJTO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(3,3-dichloroprop-2-enyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=C(Cl)Cl)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 AEJXFOVWNYZJTO-UHFFFAOYSA-N 0.000 description 2
- JGJLGBRWFGKITQ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(3-chloro-4,4,4-trifluorobut-2-enyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=C(Cl)C(F)(F)F)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 JGJLGBRWFGKITQ-UHFFFAOYSA-N 0.000 description 2
- ZBMHASDARSEIEJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(3-chlorobut-2-enyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound CN1C(=O)C=2N(CC=C(Cl)C)C(N3CC(N)CCC3)=NC=2N=C1CCC1=CC=CC=C1 ZBMHASDARSEIEJ-UHFFFAOYSA-N 0.000 description 2
- LMRUTLWDURUNSL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(cyclohexen-1-ylmethyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3CCCCC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 LMRUTLWDURUNSL-UHFFFAOYSA-N 0.000 description 2
- PPKDYANCRFNQLP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(cyclohexylmethyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC3CCCCC3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 PPKDYANCRFNQLP-UHFFFAOYSA-N 0.000 description 2
- SZNGHRDJOPIBRB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-(furan-2-ylmethyl)-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3OC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 SZNGHRDJOPIBRB-UHFFFAOYSA-N 0.000 description 2
- ZSNKHTXXIPWMSN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[(2-chlorophenyl)methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C(=CC=CC=3)Cl)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 ZSNKHTXXIPWMSN-UHFFFAOYSA-N 0.000 description 2
- CDZDXRRTYLANGN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[(2-methoxyphenyl)methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound COC1=CC=CC=C1CN1C(C(=O)N(C)C(CCC=2C=CC=CC=2)=N2)=C2N=C1N1CC(N)CCC1 CDZDXRRTYLANGN-UHFFFAOYSA-N 0.000 description 2
- QJCNFDMECJZPQU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[(3,4-difluorophenyl)methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(F)C(F)=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 QJCNFDMECJZPQU-UHFFFAOYSA-N 0.000 description 2
- BRGKDZMBIKRQGZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[(3-bromophenyl)methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(Br)C=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 BRGKDZMBIKRQGZ-UHFFFAOYSA-N 0.000 description 2
- FZDZRZNQLRLCGL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[(4-fluorophenyl)methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC(F)=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 FZDZRZNQLRLCGL-UHFFFAOYSA-N 0.000 description 2
- AJDXZDFFHUPNRJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-[[3-(difluoromethoxy)phenyl]methyl]-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=C(OC(F)F)C=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 AJDXZDFFHUPNRJ-UHFFFAOYSA-N 0.000 description 2
- ZOYFLQQOAHGFQF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1,2-dimethylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C)=NC=2N=C1N1CCCC(N)C1 ZOYFLQQOAHGFQF-UHFFFAOYSA-N 0.000 description 2
- PSWJMFKZJDPESK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(2-cyclohexyl-2-oxoethyl)-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C1CCCCC1)C(CCC=1C=CC=CC=1)=N2 PSWJMFKZJDPESK-UHFFFAOYSA-N 0.000 description 2
- GBXWXNIENFNLHA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(2-methylpropyl)-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC(C)C)C=1CCC1=CC=CC=C1 GBXWXNIENFNLHA-UHFFFAOYSA-N 0.000 description 2
- SHVXDJXVJHCYKM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(2-oxo-2-pyridin-3-ylethyl)-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=NC=CC=1)C(CCC=1C=CC=CC=1)=N2 SHVXDJXVJHCYKM-UHFFFAOYSA-N 0.000 description 2
- DJEWROVKJMKNJJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(2-oxo-2-thiophen-2-ylethyl)-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1SC=CC=1)C(CCC=1C=CC=CC=1)=N2 DJEWROVKJMKNJJ-UHFFFAOYSA-N 0.000 description 2
- FRZCQPMSNUILCI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(2-oxopropyl)-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC(=O)C)C=1CCC1=CC=CC=C1 FRZCQPMSNUILCI-UHFFFAOYSA-N 0.000 description 2
- TXAFAUAMLDZBPT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CCC=1C=CC=CC=1)C=N2 TXAFAUAMLDZBPT-UHFFFAOYSA-N 0.000 description 2
- IGSBBMGEAKIJLD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(3-methylbut-2-enyl)-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC=C(C)C)C=1CCC1=CC=CC=C1 IGSBBMGEAKIJLD-UHFFFAOYSA-N 0.000 description 2
- MEOXXXOHZZYHPG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(3-methylbutyl)-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCC(C)C)C=1CCC1=CC=CC=C1 MEOXXXOHZZYHPG-UHFFFAOYSA-N 0.000 description 2
- SPEZDYJTUIHHLM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(4-methylpentyl)-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCC(C)C)C=1CCC1=CC=CC=C1 SPEZDYJTUIHHLM-UHFFFAOYSA-N 0.000 description 2
- VRQIZTXSIXLEFG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(cyclohexylmethyl)-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC1CCCCC1)C(CCC=1C=CC=CC=1)=N2 VRQIZTXSIXLEFG-UHFFFAOYSA-N 0.000 description 2
- SIZOCPXUQDDGME-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(cyclopropylmethyl)-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC1CC1)C(CCC=1C=CC=CC=1)=N2 SIZOCPXUQDDGME-UHFFFAOYSA-N 0.000 description 2
- UJDIFSBOEVETBY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(isoquinolin-1-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C3=CC=CC=C3C=CN=1)C=N2 UJDIFSBOEVETBY-UHFFFAOYSA-N 0.000 description 2
- XHEXWCPZUQQYAC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(naphthalen-1-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C3=CC=CC=C3C=CC=1)C=N2 XHEXWCPZUQQYAC-UHFFFAOYSA-N 0.000 description 2
- UNHHZHHPZZSDIK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(quinolin-4-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C3=CC=CC=C3N=CC=1)C=N2 UNHHZHHPZZSDIK-UHFFFAOYSA-N 0.000 description 2
- PNYOPETVTLUXEH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(2,4-dimethoxyphenyl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1CCC1=CC=CC=C1 PNYOPETVTLUXEH-UHFFFAOYSA-N 0.000 description 2
- JYFDMHZVPPMDGD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(2,4-dimethylphenyl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound CC1=CC(C)=CC=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1CCC1=CC=CC=C1 JYFDMHZVPPMDGD-UHFFFAOYSA-N 0.000 description 2
- FPDPCTGIJZVRQT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(2-fluorophenyl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C(=CC=CC=1)F)C(CCC=1C=CC=CC=1)=N2 FPDPCTGIJZVRQT-UHFFFAOYSA-N 0.000 description 2
- XYTRIIIUDXCOHE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(3-methyl-1,2-oxazol-5-yl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound O1N=C(C)C=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1CCC1=CC=CC=C1 XYTRIIIUDXCOHE-UHFFFAOYSA-N 0.000 description 2
- RLGUDMXAXARJKV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(4,5-dimethyl-1,3-oxazol-2-yl)methyl]purin-6-one Chemical compound O1C(C)=C(C)N=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 RLGUDMXAXARJKV-UHFFFAOYSA-N 0.000 description 2
- MBPAPQYAAGESDI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(4,5-dimethyl-1,3-thiazol-2-yl)methyl]purin-6-one Chemical compound S1C(C)=C(C)N=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 MBPAPQYAAGESDI-UHFFFAOYSA-N 0.000 description 2
- GPYXEEGZNNSMLJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(4,6-dimethylpyrimidin-2-yl)methyl]purin-6-one Chemical compound CC1=CC(C)=NC(CN2C(C=3N(CC=4C=CC=CC=4)C(N4CC(N)CCC4)=NC=3N=C2)=O)=N1 GPYXEEGZNNSMLJ-UHFFFAOYSA-N 0.000 description 2
- SOUYYRGBWZUUBE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(4-chlorophenyl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=CC(Cl)=CC=1)C(CCC=1C=CC=CC=1)=N2 SOUYYRGBWZUUBE-UHFFFAOYSA-N 0.000 description 2
- QYEKCIPKOXQVCY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[(4-methylphenyl)methyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1=CC(C)=CC=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1CCC1=CC=CC=C1 QYEKCIPKOXQVCY-UHFFFAOYSA-N 0.000 description 2
- FPNOXRYMPOKSEB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-(2,4-dichlorophenyl)-2-oxoethyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C(=CC(Cl)=CC=1)Cl)C(CCC=1C=CC=CC=1)=N2 FPNOXRYMPOKSEB-UHFFFAOYSA-N 0.000 description 2
- ILJMYOFXRFXNOX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-(2-hydroxyphenyl)-2-oxoethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C(=CC=CC=1)O)C=N2 ILJMYOFXRFXNOX-UHFFFAOYSA-N 0.000 description 2
- XNCMOYRGJVCLBO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-(2-methoxyphenyl)-2-oxoethyl]purin-6-one Chemical compound COC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 XNCMOYRGJVCLBO-UHFFFAOYSA-N 0.000 description 2
- MCCFVWDAGAQQMN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-(4-methoxyphenyl)-2-oxoethyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1=CC(OC)=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1CCC1=CC=CC=C1 MCCFVWDAGAQQMN-UHFFFAOYSA-N 0.000 description 2
- GZHATSMRUQZPDE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-(4-methylphenyl)-2-oxoethyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1=CC(C)=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1CCC1=CC=CC=C1 GZHATSMRUQZPDE-UHFFFAOYSA-N 0.000 description 2
- LKRZHCOOMISROM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-(furan-2-yl)-2-oxoethyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1OC=CC=1)C(CCC=1C=CC=CC=1)=N2 LKRZHCOOMISROM-UHFFFAOYSA-N 0.000 description 2
- PNSPWRHABXQTGC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-[4-(difluoromethoxy)phenyl]-2-oxoethyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC(OC(F)F)=CC=1)C(CCC=1C=CC=CC=1)=N2 PNSPWRHABXQTGC-UHFFFAOYSA-N 0.000 description 2
- WKIVSTZQHQFHLM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-oxo-2-[4-(trifluoromethoxy)phenyl]ethyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC(OC(F)(F)F)=CC=1)C(CCC=1C=CC=CC=1)=N2 WKIVSTZQHQFHLM-UHFFFAOYSA-N 0.000 description 2
- ASJYBUSEOUBBII-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[2-oxo-2-[4-(trifluoromethyl)phenyl]ethyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC(=CC=1)C(F)(F)F)C(CCC=1C=CC=CC=1)=N2 ASJYBUSEOUBBII-UHFFFAOYSA-N 0.000 description 2
- DKBLYLMNOASTGT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-[[3-(difluoromethoxy)phenyl]methyl]-2-(2-phenylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=C(OC(F)F)C=CC=1)C(CCC=1C=CC=CC=1)=N2 DKBLYLMNOASTGT-UHFFFAOYSA-N 0.000 description 2
- JHSKTCXSAZOOQN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-butyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCC)C=1CCC1=CC=CC=C1 JHSKTCXSAZOOQN-UHFFFAOYSA-N 0.000 description 2
- FCRGCPJOWAVWGJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-ethyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC)C=1CCC1=CC=CC=C1 FCRGCPJOWAVWGJ-UHFFFAOYSA-N 0.000 description 2
- HXPLOJURYFYFKC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-hexyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCCCC)C=1CCC1=CC=CC=C1 HXPLOJURYFYFKC-UHFFFAOYSA-N 0.000 description 2
- JVSISJSQEOCVCW-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-methylpropyl)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CC(C)C)=NC=2N=C1N1CCCC(N)C1 JVSISJSQEOCVCW-UHFFFAOYSA-N 0.000 description 2
- YNXCEOFYSXWHMQ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-methylpropylamino)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(C)C)=NC=2N=C1N1CCCC(N)C1 YNXCEOFYSXWHMQ-UHFFFAOYSA-N 0.000 description 2
- DJWYGSCVGNTGIK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-methylsulfanylethylamino)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCSC)=NC=2N=C1N1CCCC(N)C1 DJWYGSCVGNTGIK-UHFFFAOYSA-N 0.000 description 2
- CNWUMMOGHJDFCZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenoxyethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCOC1=CC=CC=C1 CNWUMMOGHJDFCZ-UHFFFAOYSA-N 0.000 description 2
- ZMTXMYOOTIGTSG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethenyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC=C1 ZMTXMYOOTIGTSG-UHFFFAOYSA-N 0.000 description 2
- JZQVRWYARMXWGI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 JZQVRWYARMXWGI-UHFFFAOYSA-N 0.000 description 2
- QRRGLABMPXVARK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethylamino)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCC1=CC=CC=C1 QRRGLABMPXVARK-UHFFFAOYSA-N 0.000 description 2
- CPLQPGPYRKGQTC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethylsulfanyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1SCCC1=CC=CC=C1 CPLQPGPYRKGQTC-UHFFFAOYSA-N 0.000 description 2
- RSJCCIOBKLLLAH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylsulfanylethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCSC1=CC=CC=C1 RSJCCIOBKLLLAH-UHFFFAOYSA-N 0.000 description 2
- URWUAIVSNLUALM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(2-pyridin-2-ylethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCC1=CC=CC=N1 URWUAIVSNLUALM-UHFFFAOYSA-N 0.000 description 2
- MDTWTTKMZFPJHM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(3-methylbut-2-enyl)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CC=C(C)C)=NC=2N=C1N1CCCC(N)C1 MDTWTTKMZFPJHM-UHFFFAOYSA-N 0.000 description 2
- FBONEQBOEFBZJV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(3-methylbutyl)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCC(C)C)=NC=2N=C1N1CCCC(N)C1 FBONEQBOEFBZJV-UHFFFAOYSA-N 0.000 description 2
- OCWOILMUCVOHSK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(3-phenylprop-2-enyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC=CC1=CC=CC=C1 OCWOILMUCVOHSK-UHFFFAOYSA-N 0.000 description 2
- CEQSSXVDDQUNKO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(3-phenylpropyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCCC1=CC=CC=C1 CEQSSXVDDQUNKO-UHFFFAOYSA-N 0.000 description 2
- ZFKSENLRTKJDEK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(4-methylpentyl)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCC(C)C)=NC=2N=C1N1CCCC(N)C1 ZFKSENLRTKJDEK-UHFFFAOYSA-N 0.000 description 2
- YQFWRJKMRQAPES-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(4-methylpiperazin-1-yl)purin-6-one Chemical compound C1CN(C)CCN1C(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 YQFWRJKMRQAPES-UHFFFAOYSA-N 0.000 description 2
- WHCXDZPBBIMTDS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(methylamino)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NC)=NC=2N=C1N1CCCC(N)C1 WHCXDZPBBIMTDS-UHFFFAOYSA-N 0.000 description 2
- YXQNPRVALZMWSB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(propan-2-ylamino)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NC(C)C)=NC=2N=C1N1CCCC(N)C1 YXQNPRVALZMWSB-UHFFFAOYSA-N 0.000 description 2
- YKHCCSLRHGIASU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(propylamino)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCC)=NC=2N=C1N1CCCC(N)C1 YKHCCSLRHGIASU-UHFFFAOYSA-N 0.000 description 2
- IYSMLVQVYUVGEQ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(pyridin-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC=N1 IYSMLVQVYUVGEQ-UHFFFAOYSA-N 0.000 description 2
- OVFHJWDUJLGQTG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(thiophen-2-ylmethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CS1 OVFHJWDUJLGQTG-UHFFFAOYSA-N 0.000 description 2
- GKEOPLDMIJUMSI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(2-morpholin-4-yl-2-oxoethyl)amino]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC(=O)N1CCOCC1 GKEOPLDMIJUMSI-UHFFFAOYSA-N 0.000 description 2
- SXPWDGACCWKZOG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(3-methyl-1,2-oxazol-5-yl)methylamino]purin-6-one Chemical compound O1N=C(C)C=C1CNC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 SXPWDGACCWKZOG-UHFFFAOYSA-N 0.000 description 2
- YUWVUCXSMKDFNT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(4-methyl-1,3-thiazol-2-yl)methylamino]purin-6-one Chemical compound CC1=CSC(CNC=2N(C(=O)C=3N(CC=4C=CC=CC=4)C(N4CC(N)CCC4)=NC=3N=2)C)=N1 YUWVUCXSMKDFNT-UHFFFAOYSA-N 0.000 description 2
- NIQJJUNNUKXPIO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(4-methylphenyl)methylamino]purin-6-one Chemical compound C1=CC(C)=CC=C1CNC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 NIQJJUNNUKXPIO-UHFFFAOYSA-N 0.000 description 2
- QYTODSPMGZSARF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-(2-methylsulfonylphenyl)ethyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1S(C)(=O)=O QYTODSPMGZSARF-UHFFFAOYSA-N 0.000 description 2
- ZXNGPBYBGLBPRG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-(methylamino)ethylamino]purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCNC)=NC=2N=C1N1CCCC(N)C1 ZXNGPBYBGLBPRG-UHFFFAOYSA-N 0.000 description 2
- VTHAQAUKOCDLPD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-[3-(trifluoromethoxy)phenyl]ethenyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC(OC(F)(F)F)=C1 VTHAQAUKOCDLPD-UHFFFAOYSA-N 0.000 description 2
- KEBHFUUMRDDGDG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-[3-(trifluoromethyl)phenyl]ethenyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC(C(F)(F)F)=C1 KEBHFUUMRDDGDG-UHFFFAOYSA-N 0.000 description 2
- FYISYIRHAGIPNW-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-[3-(trifluoromethyl)phenyl]ethyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC(C(F)(F)F)=C1 FYISYIRHAGIPNW-UHFFFAOYSA-N 0.000 description 2
- OEUZBGKFPZNBIX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[[3-(trifluoromethoxy)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC(OC(F)(F)F)=C1 OEUZBGKFPZNBIX-UHFFFAOYSA-N 0.000 description 2
- YVSDXPPKCZWPSV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[[3-(trifluoromethyl)phenyl]methyl]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC(C(F)(F)F)=C1 YVSDXPPKCZWPSV-UHFFFAOYSA-N 0.000 description 2
- YYNMAJXFQCJXCR-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[[4-(trifluoromethoxy)phenyl]methylamino]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(OC(F)(F)F)C=C1 YYNMAJXFQCJXCR-UHFFFAOYSA-N 0.000 description 2
- RBFIISQFJLBWKW-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[[4-(trifluoromethyl)phenyl]methylamino]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(C(F)(F)F)C=C1 RBFIISQFJLBWKW-UHFFFAOYSA-N 0.000 description 2
- BZMCWQZOKSKYRY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[methyl(propyl)amino]purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N(C)CCC)=NC=2N=C1N1CCCC(N)C1 BZMCWQZOKSKYRY-UHFFFAOYSA-N 0.000 description 2
- SHTXEPKRVLXELJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-methylsulfanylpurin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(SC)=NC=2N=C1N1CCCC(N)C1 SHTXEPKRVLXELJ-UHFFFAOYSA-N 0.000 description 2
- FOKXYDANFVFWBF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-morpholin-4-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCOCC3)=NC=2N=C1N1CCCC(N)C1 FOKXYDANFVFWBF-UHFFFAOYSA-N 0.000 description 2
- RBLLCLSIQVHQPY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-pent-4-enylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCC=C)=NC=2N=C1N1CCCC(N)C1 RBLLCLSIQVHQPY-UHFFFAOYSA-N 0.000 description 2
- IXCOLSCXKFTMDE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-pentylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCCC)=NC=2N=C1N1CCCC(N)C1 IXCOLSCXKFTMDE-UHFFFAOYSA-N 0.000 description 2
- YWBGAJBMHNFFHR-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-phenacylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC(=O)C1=CC=CC=C1 YWBGAJBMHNFFHR-UHFFFAOYSA-N 0.000 description 2
- KGLQLNZJUAYWPY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-phenylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C=3C=CC=CC=3)=NC=2N=C1N1CCCC(N)C1 KGLQLNZJUAYWPY-UHFFFAOYSA-N 0.000 description 2
- ARKIRKYLMOEVBY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-piperazin-1-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCNCC3)=NC=2N=C1N1CCCC(N)C1 ARKIRKYLMOEVBY-UHFFFAOYSA-N 0.000 description 2
- HLANVPMVMPQUHW-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-piperidin-1-ylpurin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCCCC3)=NC=2N=C1N1CCCC(N)C1 HLANVPMVMPQUHW-UHFFFAOYSA-N 0.000 description 2
- VYBXZISXBSNGEH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-propan-2-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C(C)C)=NC=2N=C1N1CCCC(N)C1 VYBXZISXBSNGEH-UHFFFAOYSA-N 0.000 description 2
- CBAYPUCIPGLMMY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-propylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCC)=NC=2N=C1N1CCCC(N)C1 CBAYPUCIPGLMMY-UHFFFAOYSA-N 0.000 description 2
- UCPAQYHYWJHZSE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-pyridin-2-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C=3N=CC=CC=3)=NC=2N=C1N1CCCC(N)C1 UCPAQYHYWJHZSE-UHFFFAOYSA-N 0.000 description 2
- YLXMCLJUUVRELY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-pyridin-4-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C=3C=CN=CC=3)=NC=2N=C1N1CCCC(N)C1 YLXMCLJUUVRELY-UHFFFAOYSA-N 0.000 description 2
- KHWOHEHMYBJPCE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-pyrrolidin-1-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCCC3)=NC=2N=C1N1CCCC(N)C1 KHWOHEHMYBJPCE-UHFFFAOYSA-N 0.000 description 2
- FDMXWZIGALXUOM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-thiophen-2-ylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C=3SC=CC=3)=NC=2N=C1N1CCCC(N)C1 FDMXWZIGALXUOM-UHFFFAOYSA-N 0.000 description 2
- ZWJANXHNJZEDMH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurine-2-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C#N)=NC=2N=C1N1CCCC(N)C1 ZWJANXHNJZEDMH-UHFFFAOYSA-N 0.000 description 2
- NZGQGUPAFCAOJA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methylpurin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(C)C=NC=2N=C1N1CCCC(N)C1 NZGQGUPAFCAOJA-UHFFFAOYSA-N 0.000 description 2
- CCZIWTGXULXPIG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-pentyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCCC)C=1CCC1=CC=CC=C1 CCZIWTGXULXPIG-UHFFFAOYSA-N 0.000 description 2
- UQSWQJJPOGGQQO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-phenacylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC=CC=1)C=N2 UQSWQJJPOGGQQO-UHFFFAOYSA-N 0.000 description 2
- VGBGNGBUZIEHCC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-cyclohexylethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1CCCCC1 VGBGNGBUZIEHCC-UHFFFAOYSA-N 0.000 description 2
- OCJULUXPPIURNY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-cyclohexylethylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCC1CCCCC1 OCJULUXPPIURNY-UHFFFAOYSA-N 0.000 description 2
- IHELNNRBGIKBSF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-hydroxyethylamino)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCO)=NC=2N=C1N1CCCC(N)C1 IHELNNRBGIKBSF-UHFFFAOYSA-N 0.000 description 2
- KBVWYFIMMMNWEO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-methoxyethylamino)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCOC)=NC=2N=C1N1CCCC(N)C1 KBVWYFIMMMNWEO-UHFFFAOYSA-N 0.000 description 2
- AGQBLUFXQUPLEF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-phenylethyl)-1-(pyridin-4-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=CN=CC=1)C(CCC=1C=CC=CC=1)=N2 AGQBLUFXQUPLEF-UHFFFAOYSA-N 0.000 description 2
- GFZSGBMKRVPZDY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-phenylethyl)-1-(thiophen-2-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1SC=CC=1)C(CCC=1C=CC=CC=1)=N2 GFZSGBMKRVPZDY-UHFFFAOYSA-N 0.000 description 2
- KQVYHDOJEKHULO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-phenylethyl)-1-[[3-(trifluoromethoxy)phenyl]methyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=C(OC(F)(F)F)C=CC=1)C(CCC=1C=CC=CC=1)=N2 KQVYHDOJEKHULO-UHFFFAOYSA-N 0.000 description 2
- PKCYYJAOUHCOKS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-phenylethyl)-1-[[3-(trifluoromethyl)phenyl]methyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=C(C=CC=1)C(F)(F)F)C(CCC=1C=CC=CC=1)=N2 PKCYYJAOUHCOKS-UHFFFAOYSA-N 0.000 description 2
- JGUCKNXCXKVYIL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-phenylethyl)-1-propan-2-ylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C(C)C)C=1CCC1=CC=CC=C1 JGUCKNXCXKVYIL-UHFFFAOYSA-N 0.000 description 2
- OTOANSFVEYBSPD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(2-phenylethyl)-1-propylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCC)C=1CCC1=CC=CC=C1 OTOANSFVEYBSPD-UHFFFAOYSA-N 0.000 description 2
- WVYQDHRTCQZTOR-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(3-cyclohexylpropylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCCC1CCCCC1 WVYQDHRTCQZTOR-UHFFFAOYSA-N 0.000 description 2
- YNGKQHRUSMAYDH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(3-methoxypropylamino)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCCOC)=NC=2N=C1N1CCCC(N)C1 YNGKQHRUSMAYDH-UHFFFAOYSA-N 0.000 description 2
- BEQCUZYRQKHANP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(2-methylpropyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC(C)C)C=1NCC1=CC=CC=C1 BEQCUZYRQKHANP-UHFFFAOYSA-N 0.000 description 2
- ARPWTWBFTBESEM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(2-oxo-2-pyridin-3-ylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=NC=CC=1)C(NCC=1C=CC=CC=1)=N2 ARPWTWBFTBESEM-UHFFFAOYSA-N 0.000 description 2
- CSRMUTJKUKNHTO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(2-oxo-2-thiophen-2-ylethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1SC=CC=1)C(NCC=1C=CC=CC=1)=N2 CSRMUTJKUKNHTO-UHFFFAOYSA-N 0.000 description 2
- HXWQZVWDSUEFRU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(3-methylbut-2-enyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC=C(C)C)C=1NCC1=CC=CC=C1 HXWQZVWDSUEFRU-UHFFFAOYSA-N 0.000 description 2
- UWQCGERNMURRHS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(3-methylbutyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCC(C)C)C=1NCC1=CC=CC=C1 UWQCGERNMURRHS-UHFFFAOYSA-N 0.000 description 2
- PRSOTPZQRDQXMD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(4-methylpentyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCC(C)C)C=1NCC1=CC=CC=C1 PRSOTPZQRDQXMD-UHFFFAOYSA-N 0.000 description 2
- ASXXPCAZXRTSEU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(cyclohexylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC1CCCCC1)C(NCC=1C=CC=CC=1)=N2 ASXXPCAZXRTSEU-UHFFFAOYSA-N 0.000 description 2
- ZQGWISQRKYCGOP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(cyclopropylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC1CC1)C(NCC=1C=CC=CC=1)=N2 ZQGWISQRKYCGOP-UHFFFAOYSA-N 0.000 description 2
- VBXCIKRPLUZUEJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(furan-2-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1OC=CC=1)C(NCC=1C=CC=CC=1)=N2 VBXCIKRPLUZUEJ-UHFFFAOYSA-N 0.000 description 2
- GXNHXSBRFKPJAQ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(pyridin-4-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=CN=CC=1)C(NCC=1C=CC=CC=1)=N2 GXNHXSBRFKPJAQ-UHFFFAOYSA-N 0.000 description 2
- NIFZCVWFNVTROB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(thiophen-2-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1SC=CC=1)C(NCC=1C=CC=CC=1)=N2 NIFZCVWFNVTROB-UHFFFAOYSA-N 0.000 description 2
- OXJAWLNSOZOBPU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(2,4-dimethoxyphenyl)methyl]purin-6-one Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 OXJAWLNSOZOBPU-UHFFFAOYSA-N 0.000 description 2
- RLBLLUJMKRKDFI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(2,4-dimethylphenyl)methyl]purin-6-one Chemical compound CC1=CC(C)=CC=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 RLBLLUJMKRKDFI-UHFFFAOYSA-N 0.000 description 2
- PNZWJAOYRZEADH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(3-methyl-1,2-oxazol-5-yl)methyl]purin-6-one Chemical compound O1N=C(C)C=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 PNZWJAOYRZEADH-UHFFFAOYSA-N 0.000 description 2
- WZELSLVZRDFEDD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(4-chlorophenyl)methyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=CC(Cl)=CC=1)C(NCC=1C=CC=CC=1)=N2 WZELSLVZRDFEDD-UHFFFAOYSA-N 0.000 description 2
- QWIAOYMGHWMLBJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[(4-methylphenyl)methyl]purin-6-one Chemical compound C1=CC(C)=CC=C1CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 QWIAOYMGHWMLBJ-UHFFFAOYSA-N 0.000 description 2
- JDSDXBOWAXMCIR-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-(2,4-dichlorophenyl)-2-oxoethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C(=CC(Cl)=CC=1)Cl)C(NCC=1C=CC=CC=1)=N2 JDSDXBOWAXMCIR-UHFFFAOYSA-N 0.000 description 2
- CXDULZDQSPGGDZ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-(4-methoxyphenyl)-2-oxoethyl]purin-6-one Chemical compound C1=CC(OC)=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 CXDULZDQSPGGDZ-UHFFFAOYSA-N 0.000 description 2
- YYYQOYZYSNETDO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-(4-methylphenyl)-2-oxoethyl]purin-6-one Chemical compound C1=CC(C)=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1NCC1=CC=CC=C1 YYYQOYZYSNETDO-UHFFFAOYSA-N 0.000 description 2
- SEOFULGWOOEQKD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-(furan-2-yl)-2-oxoethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1OC=CC=1)C(NCC=1C=CC=CC=1)=N2 SEOFULGWOOEQKD-UHFFFAOYSA-N 0.000 description 2
- PEJMQYYSHJMTCL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-[4-(difluoromethoxy)phenyl]-2-oxoethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC(OC(F)F)=CC=1)C(NCC=1C=CC=CC=1)=N2 PEJMQYYSHJMTCL-UHFFFAOYSA-N 0.000 description 2
- UKNUBAIFRJMNCF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-oxo-2-[4-(trifluoromethoxy)phenyl]ethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC(OC(F)(F)F)=CC=1)C(NCC=1C=CC=CC=1)=N2 UKNUBAIFRJMNCF-UHFFFAOYSA-N 0.000 description 2
- NLSQFLWEFVTZKJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[2-oxo-2-[4-(trifluoromethyl)phenyl]ethyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC(=O)C=1C=CC(=CC=1)C(F)(F)F)C(NCC=1C=CC=CC=1)=N2 NLSQFLWEFVTZKJ-UHFFFAOYSA-N 0.000 description 2
- AASCIABTPSKJIE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[[3-(difluoromethoxy)phenyl]methyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=C(OC(F)F)C=CC=1)C(NCC=1C=CC=CC=1)=N2 AASCIABTPSKJIE-UHFFFAOYSA-N 0.000 description 2
- SIIRKSYYFHKZPQ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[[3-(trifluoromethoxy)phenyl]methyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=C(OC(F)(F)F)C=CC=1)C(NCC=1C=CC=CC=1)=N2 SIIRKSYYFHKZPQ-UHFFFAOYSA-N 0.000 description 2
- IIWKWNGZUAZNQM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-[[3-(trifluoromethyl)phenyl]methyl]purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=C(C=CC=1)C(F)(F)F)C(NCC=1C=CC=CC=1)=N2 IIWKWNGZUAZNQM-UHFFFAOYSA-N 0.000 description 2
- QXWYUIGSGHARFG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-butylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCC)C=1NCC1=CC=CC=C1 QXWYUIGSGHARFG-UHFFFAOYSA-N 0.000 description 2
- COWMBNCWTNXKOG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-ethylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC)C=1NCC1=CC=CC=C1 COWMBNCWTNXKOG-UHFFFAOYSA-N 0.000 description 2
- UFPCFFWFBRMRMN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-hexylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCCCC)C=1NCC1=CC=CC=C1 UFPCFFWFBRMRMN-UHFFFAOYSA-N 0.000 description 2
- LSEPJOQVNUUIFD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-pentylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCCCC)C=1NCC1=CC=CC=C1 LSEPJOQVNUUIFD-UHFFFAOYSA-N 0.000 description 2
- AFIKIBGUWPTEKP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-propan-2-ylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C(C)C)C=1NCC1=CC=CC=C1 AFIKIBGUWPTEKP-UHFFFAOYSA-N 0.000 description 2
- JJDZCAIGGHSXLP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-propylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CCC)C=1NCC1=CC=CC=C1 JJDZCAIGGHSXLP-UHFFFAOYSA-N 0.000 description 2
- QKAULPOSPMORCP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(butylamino)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCCC)=NC=2N=C1N1CCCC(N)C1 QKAULPOSPMORCP-UHFFFAOYSA-N 0.000 description 2
- MQMCATIZRSOLPC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclobutylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1CCC1 MQMCATIZRSOLPC-UHFFFAOYSA-N 0.000 description 2
- QZPQQTHPOCIKOF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclobutylmethylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1CCC1 QZPQQTHPOCIKOF-UHFFFAOYSA-N 0.000 description 2
- QRQTZCLBERGDRY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclohexylamino)-1-methylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1CCCCC1 QRQTZCLBERGDRY-UHFFFAOYSA-N 0.000 description 2
- SZFPMAWWDKIRRT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclohexylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1CCCCC1 SZFPMAWWDKIRRT-UHFFFAOYSA-N 0.000 description 2
- JRQQCSZVFBUCTP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclohexylmethylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1CCCCC1 JRQQCSZVFBUCTP-UHFFFAOYSA-N 0.000 description 2
- ZQTVLUMISDWHHA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclohexylmethylamino)-1-methylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1CCCCC1 ZQTVLUMISDWHHA-UHFFFAOYSA-N 0.000 description 2
- IVYNXBUBDULVCG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclopentylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1CCCC1 IVYNXBUBDULVCG-UHFFFAOYSA-N 0.000 description 2
- XSFPYYYLCAIBPG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclopentylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1CCCC1 XSFPYYYLCAIBPG-UHFFFAOYSA-N 0.000 description 2
- NDTHHJKCWYDCOV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclopentylmethylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1CCCC1 NDTHHJKCWYDCOV-UHFFFAOYSA-N 0.000 description 2
- JADVLLOOEMEDRD-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(cyclopropylmethylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1CC1 JADVLLOOEMEDRD-UHFFFAOYSA-N 0.000 description 2
- IJOQAGLOLNEDRX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(diethylamino)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N(CC)CC)=NC=2N=C1N1CCCC(N)C1 IJOQAGLOLNEDRX-UHFFFAOYSA-N 0.000 description 2
- DDTSUZKXIYLGRL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(dimethylamino)-1-methylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N(C)C)=NC=2N=C1N1CCCC(N)C1 DDTSUZKXIYLGRL-UHFFFAOYSA-N 0.000 description 2
- NKCYXOZCCDYXTO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(ethylamino)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC)=NC=2N=C1N1CCCC(N)C1 NKCYXOZCCDYXTO-UHFFFAOYSA-N 0.000 description 2
- DFVLBFNFVHNKNA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(furan-2-yl)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C=3OC=CC=3)=NC=2N=C1N1CCCC(N)C1 DFVLBFNFVHNKNA-UHFFFAOYSA-N 0.000 description 2
- FSWAORDNQRYVHS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(furan-2-ylmethyl)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CO1 FSWAORDNQRYVHS-UHFFFAOYSA-N 0.000 description 2
- GZTVCCYTFWUEHV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(isoquinolin-1-ylmethylamino)-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC=3C4=CC=CC=C4C=CN=3)=NC=2N=C1N1CCCC(N)C1 GZTVCCYTFWUEHV-UHFFFAOYSA-N 0.000 description 2
- YSJDNHTUASPRJU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(3,4-dichlorophenyl)methylamino]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(Cl)C(Cl)=C1 YSJDNHTUASPRJU-UHFFFAOYSA-N 0.000 description 2
- KWMVZWFBEVEENG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(3-bromophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC(Br)=C1 KWMVZWFBEVEENG-UHFFFAOYSA-N 0.000 description 2
- JJWWGJJVWCHXES-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(3-chlorophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=CC(Cl)=C1 JJWWGJJVWCHXES-UHFFFAOYSA-N 0.000 description 2
- UWBSEEKRBHJVEH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(3-methoxyphenyl)methyl]-1-methylpurin-6-one Chemical compound COC1=CC=CC(CC=2N(C(=O)C=3N(CC=4C=CC=CC=4)C(N4CC(N)CCC4)=NC=3N=2)C)=C1 UWBSEEKRBHJVEH-UHFFFAOYSA-N 0.000 description 2
- KBPPOWJLRLRGKY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(4,5-dimethyl-1,3-oxazol-2-yl)methylamino]-1-methylpurin-6-one Chemical compound O1C(C)=C(C)N=C1CNC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 KBPPOWJLRLRGKY-UHFFFAOYSA-N 0.000 description 2
- UNQKNYKMOFDSDV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(4-fluorophenyl)methyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CC1=CC=C(F)C=C1 UNQKNYKMOFDSDV-UHFFFAOYSA-N 0.000 description 2
- LYJDRLPVJWTZKU-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(4-fluorophenyl)methylamino]-1-methylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(F)C=C1 LYJDRLPVJWTZKU-UHFFFAOYSA-N 0.000 description 2
- YKNKQJATMBNEBH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[(4-methoxyphenyl)methylamino]-1-methylpurin-6-one Chemical compound C1=CC(OC)=CC=C1CNC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 YKNKQJATMBNEBH-UHFFFAOYSA-N 0.000 description 2
- HRCMCAZOTHKPGS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(3,4-dimethoxyphenyl)ethenyl]-1-methylpurin-6-one Chemical compound C1=C(OC)C(OC)=CC=C1C=CC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 HRCMCAZOTHKPGS-UHFFFAOYSA-N 0.000 description 2
- PIHTYSGEFVMMAJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-hydroxyethyl(methyl)amino]-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N(CCO)C)=NC=2N=C1N1CCCC(N)C1 PIHTYSGEFVMMAJ-UHFFFAOYSA-N 0.000 description 2
- SKWUKKBVTSKWKN-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-methoxyethyl(methyl)amino]-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N(C)CCOC)=NC=2N=C1N1CCCC(N)C1 SKWUKKBVTSKWKN-UHFFFAOYSA-N 0.000 description 2
- XAFOOIBQIKMFKF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[3-(dimethylamino)propylamino]-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCCN(C)C)=NC=2N=C1N1CCCC(N)C1 XAFOOIBQIKMFKF-UHFFFAOYSA-N 0.000 description 2
- ZHSKBZCJGINKHI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[[4-(difluoromethoxy)phenyl]methylamino]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=C(OC(F)F)C=C1 ZHSKBZCJGINKHI-UHFFFAOYSA-N 0.000 description 2
- HYOBSUDIGAKKJR-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[butyl(methyl)amino]-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N(C)CCCC)=NC=2N=C1N1CCCC(N)C1 HYOBSUDIGAKKJR-UHFFFAOYSA-N 0.000 description 2
- KCVDBIXCGZSKFH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[ethyl(methyl)amino]-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N(C)CC)=NC=2N=C1N1CCCC(N)C1 KCVDBIXCGZSKFH-UHFFFAOYSA-N 0.000 description 2
- GPQOSSCLFVBKQA-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-benzylsulfanyl-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1SCC1=CC=CC=C1 GPQOSSCLFVBKQA-UHFFFAOYSA-N 0.000 description 2
- UFVDMGHRYOTQOX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-benzylsulfanyl-3h-purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N=C(SCC=1C=CC=CC=1)N2 UFVDMGHRYOTQOX-UHFFFAOYSA-N 0.000 description 2
- NYFBBLZNGYQCAE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-butyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCC)=NC=2N=C1N1CCCC(N)C1 NYFBBLZNGYQCAE-UHFFFAOYSA-N 0.000 description 2
- GJRLQXVOPDYYJI-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-cyclohexyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C3CCCCC3)=NC=2N=C1N1CCCC(N)C1 GJRLQXVOPDYYJI-UHFFFAOYSA-N 0.000 description 2
- FTKQPIQQXHKWEG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-cyclopentyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(C3CCCC3)=NC=2N=C1N1CCCC(N)C1 FTKQPIQQXHKWEG-UHFFFAOYSA-N 0.000 description 2
- OTNUTFMNMNJFPJ-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-ethyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CC)=NC=2N=C1N1CCCC(N)C1 OTNUTFMNMNJFPJ-UHFFFAOYSA-N 0.000 description 2
- DGAUHGLZDHQOAT-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-hex-5-enyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCCC=C)=NC=2N=C1N1CCCC(N)C1 DGAUHGLZDHQOAT-UHFFFAOYSA-N 0.000 description 2
- DMSLPMPVUZBCFM-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-hexyl-1-methylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CCCCCC)=NC=2N=C1N1CCCC(N)C1 DMSLPMPVUZBCFM-UHFFFAOYSA-N 0.000 description 2
- LIIVCHKCCYQBAO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-methylsulfanyl-1-(2-phenylethyl)purin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(CCC=3C=CC=CC=3)C(SC)=NC=2N=C1N1CCCC(N)C1 LIIVCHKCCYQBAO-UHFFFAOYSA-N 0.000 description 2
- JKKVVPOLSIWJIF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-methylsulfanyl-1-phenacylpurin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)N(CC(=O)C=3C=CC=CC=3)C(SC)=NC=2N=C1N1CCCC(N)C1 JKKVVPOLSIWJIF-UHFFFAOYSA-N 0.000 description 2
- WSCQYLYICZOBJS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-methylsulfanyl-3h-purin-6-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CN1C=2C(=O)NC(SC)=NC=2N=C1N1CCCC(N)C1 WSCQYLYICZOBJS-UHFFFAOYSA-N 0.000 description 2
- POPGOKSVSIXPFN-UHFFFAOYSA-N 8-(3-aminopyrrolidin-1-yl)-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 POPGOKSVSIXPFN-UHFFFAOYSA-N 0.000 description 2
- GWFFCDILFMQZQV-UHFFFAOYSA-N 8-(3-aminopyrrolidin-1-yl)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 GWFFCDILFMQZQV-UHFFFAOYSA-N 0.000 description 2
- UMDOHRAMLXMCHJ-UHFFFAOYSA-N 8-(4-aminoazepan-1-yl)-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(N3CCC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 UMDOHRAMLXMCHJ-UHFFFAOYSA-N 0.000 description 2
- GFPLJWLITWRUMT-UHFFFAOYSA-N 8-(4-aminoazepan-1-yl)-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CCC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 GFPLJWLITWRUMT-UHFFFAOYSA-N 0.000 description 2
- HGXKPNSBDPVZOS-UHFFFAOYSA-N 8-[(2-aminocyclohexyl)amino]-7-benzyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound N=1C=2N=C(NC3C(CCCC3)N)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1 HGXKPNSBDPVZOS-UHFFFAOYSA-N 0.000 description 2
- QNGNFOLXDVRAMB-UHFFFAOYSA-N 8-[(2-aminocyclohexyl)amino]-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(NC3C(CCCC3)N)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=C1 QNGNFOLXDVRAMB-UHFFFAOYSA-N 0.000 description 2
- JGNHKCGUBNXEOU-UHFFFAOYSA-N 8-[2-aminoethyl(ethyl)amino]-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC=3C=CC=CC=3)C(N(CCN)CC)=NC=2N=C1NCC1=CC=CC=C1 JGNHKCGUBNXEOU-UHFFFAOYSA-N 0.000 description 2
- WSQGDCFBADLRKX-UHFFFAOYSA-N 8-[2-aminoethyl(methyl)amino]-7-benzyl-2-(benzylamino)-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC=3C=CC=CC=3)C(N(CCN)C)=NC=2N=C1NCC1=CC=CC=C1 WSQGDCFBADLRKX-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 0 CC(N(*)C1=O)=Nc2c1[n](*)c(*)n2 Chemical compound CC(N(*)C1=O)=Nc2c1[n](*)c(*)n2 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- RKFJLAMKBRRYJG-UHFFFAOYSA-M [Br-].[Mg+]CCC1=CC=CC=C1 Chemical compound [Br-].[Mg+]CCC1=CC=CC=C1 RKFJLAMKBRRYJG-UHFFFAOYSA-M 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- AFDCLFJBXACOQE-UHFFFAOYSA-N ethyl 2-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenoxy]acetate Chemical compound CCOC(=O)COC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 AFDCLFJBXACOQE-UHFFFAOYSA-N 0.000 description 2
- PPKCNVQNYROZBN-UHFFFAOYSA-N ethyl 2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]acetate Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC(=O)OCC)=NC=2N=C1N1CCCC(N)C1 PPKCNVQNYROZBN-UHFFFAOYSA-N 0.000 description 2
- RJAJJMVNETWLGL-UHFFFAOYSA-N ethyl 5-acetamido-3-(3-methylbut-2-enyl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]imidazole-4-carboxylate Chemical compound CC(C)=CCN1C(C(=O)OCC)=C(NC(C)=O)N=C1N1CC(NC(=O)OC(C)(C)C)CCC1 RJAJJMVNETWLGL-UHFFFAOYSA-N 0.000 description 2
- BODCLJQJAXTTMM-UHFFFAOYSA-N ethyl 5-amino-3-(3-methylbut-2-enyl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]imidazole-4-carboxylate Chemical compound CC(C)=CCN1C(C(=O)OCC)=C(N)N=C1N1CC(NC(=O)OC(C)(C)C)CCC1 BODCLJQJAXTTMM-UHFFFAOYSA-N 0.000 description 2
- IGXDTSLACPPGCV-UHFFFAOYSA-N ethyl 5-amino-3-benzyl-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]imidazole-4-carboxylate Chemical compound C=1C=CC=CC=1CN1C(C(=O)OCC)=C(N)N=C1N1CCCC(NC(=O)OC(C)(C)C)C1 IGXDTSLACPPGCV-UHFFFAOYSA-N 0.000 description 2
- NGHHVVIGKWKBFA-UHFFFAOYSA-N ethyl 5-isocyano-3-(3-methylbut-2-enyl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]imidazole-4-carboxylate Chemical compound CC(C)=CCN1C(C(=O)OCC)=C([N+]#[C-])N=C1N1CC(NC(=O)OC(C)(C)C)CCC1 NGHHVVIGKWKBFA-UHFFFAOYSA-N 0.000 description 2
- QRPCEFJWXVWWHQ-UHFFFAOYSA-N ethyl n-[2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]ethyl]carbamate Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCNC(=O)OCC)=NC=2N=C1N1CCCC(N)C1 QRPCEFJWXVWWHQ-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 210000002660 insulin-secreting cell Anatomy 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- FCELOWHWFAVYDH-UHFFFAOYSA-N n-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 FCELOWHWFAVYDH-UHFFFAOYSA-N 0.000 description 2
- JRVPNEOAXCUHNN-UHFFFAOYSA-N n-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-6-oxopurin-1-yl]acetyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C(=O)CN1C(=O)C(N(CC=2C=CC=CC=2)C(N2CC(N)CCC2)=N2)=C2N=C1 JRVPNEOAXCUHNN-UHFFFAOYSA-N 0.000 description 2
- QFJDXSJIENIQSB-UHFFFAOYSA-N n-[2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]ethyl]acetamide Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCNC(=O)C)=NC=2N=C1N1CCCC(N)C1 QFJDXSJIENIQSB-UHFFFAOYSA-N 0.000 description 2
- XHFVDPSNHQGBFL-UHFFFAOYSA-N n-[2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]ethyl]benzamide Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCNC(=O)C1=CC=CC=C1 XHFVDPSNHQGBFL-UHFFFAOYSA-N 0.000 description 2
- UWUFKRPWUNRNOG-UHFFFAOYSA-N n-[2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]ethyl]benzenesulfonamide Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCCNS(=O)(=O)C1=CC=CC=C1 UWUFKRPWUNRNOG-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical group 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- DIFJJAAPMDHQSE-UHFFFAOYSA-N tert-butyl N-[1-[5-methyl-1-(3-methylbut-2-enyl)-7-oxoimidazo[4,5-d][1,3]oxazin-2-yl]piperidin-3-yl]carbamate Chemical compound CC1=NC2=C(C(=O)O1)N(C(=N2)N3CCCC(C3)NC(=O)OC(C)(C)C)CC=C(C)C DIFJJAAPMDHQSE-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 229940075966 (+)- menthol Drugs 0.000 description 1
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- 125000006603 (C1-C3) alkylaminosulfonyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ILFIRBGRMCGNOO-UHFFFAOYSA-N 1,1-bis($l^{1}-oxidanyl)ethene Chemical group [O]C([O])=C ILFIRBGRMCGNOO-UHFFFAOYSA-N 0.000 description 1
- WJUKOGPNGRUXMG-UHFFFAOYSA-N 1,2-dibromo-1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)(Br)C(Cl)(Cl)Br WJUKOGPNGRUXMG-UHFFFAOYSA-N 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- LNSCNEJNLACZPA-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(2-methylphenyl)butanedioic acid Chemical compound CC1=CC=CC=C1C(O)(C(O)=O)C(O)(C(O)=O)C1=CC=CC=C1C LNSCNEJNLACZPA-UHFFFAOYSA-N 0.000 description 1
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- VWXNAPAOLXCYGK-UHFFFAOYSA-N 2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]ethyl]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1CCC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 VWXNAPAOLXCYGK-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 1
- NAAJUEREAPVOPX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-2-(benzylamino)-7-but-2-ynyl-1-methylpurin-6-one Chemical compound CN1C(=O)C=2N(CC#CC)C(N3CC(N)CCC3)=NC=2N=C1NCC1=CC=CC=C1 NAAJUEREAPVOPX-UHFFFAOYSA-N 0.000 description 1
- MKXYBQRQWVZKQG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(pyrazin-2-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1N=CC=NC=1)C=N2 MKXYBQRQWVZKQG-UHFFFAOYSA-N 0.000 description 1
- BVNRDSCVCJZEEC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(quinazolin-2-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1N=C3C=CC=CC3=CN=1)C=N2 BVNRDSCVCJZEEC-UHFFFAOYSA-N 0.000 description 1
- SRGFGVSVZBINKL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-(quinazolin-4-ylmethyl)purin-6-one Chemical compound C1C(N)CCCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C3=CC=CC=C3N=CN=1)C=N2 SRGFGVSVZBINKL-UHFFFAOYSA-N 0.000 description 1
- MDDSYLBWGMLYND-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(3-pyridin-2-ylpropyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCCC1=CC=CC=N1 MDDSYLBWGMLYND-UHFFFAOYSA-N 0.000 description 1
- QNUKTZCGLRQPQK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(naphthalen-1-ylmethylamino)purin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCC=3C4=CC=CC=C4C=CC=3)=NC=2N=C1N1CCCC(N)C1 QNUKTZCGLRQPQK-UHFFFAOYSA-N 0.000 description 1
- YEGFHDBFTNGPTC-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(pyrazin-2-ylmethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CN=CC=N1 YEGFHDBFTNGPTC-UHFFFAOYSA-N 0.000 description 1
- OBOSNOJEUHTKIO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(pyridin-2-ylmethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CC=N1 OBOSNOJEUHTKIO-UHFFFAOYSA-N 0.000 description 1
- DWEMHQBFFXMEIW-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-(thiophen-2-ylmethylamino)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CS1 DWEMHQBFFXMEIW-UHFFFAOYSA-N 0.000 description 1
- LBTMRLXPZGRVFH-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(2-oxo-2-piperidin-1-ylethyl)amino]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC(=O)N1CCCCC1 LBTMRLXPZGRVFH-UHFFFAOYSA-N 0.000 description 1
- GRWRTUHZDJKGKK-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[(2-oxo-2-pyrrolidin-1-ylethyl)amino]purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC(=O)N1CCCC1 GRWRTUHZDJKGKK-UHFFFAOYSA-N 0.000 description 1
- WBQMLBZEKCBWFG-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-(4-methylphenyl)ethenyl]purin-6-one Chemical compound C1=CC(C)=CC=C1C=CC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 WBQMLBZEKCBWFG-UHFFFAOYSA-N 0.000 description 1
- AYURKCBVGIPMIE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-[2-(4-methylphenyl)ethyl]purin-6-one Chemical compound C1=CC(C)=CC=C1CCC(N(C1=O)C)=NC2=C1N(CC=1C=CC=CC=1)C(N1CC(N)CCC1)=N2 AYURKCBVGIPMIE-UHFFFAOYSA-N 0.000 description 1
- ZAUSEAWVDDKTJP-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-2-prop-2-ynylpurin-6-one Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(CC#C)=NC=2N=C1N1CCCC(N)C1 ZAUSEAWVDDKTJP-UHFFFAOYSA-N 0.000 description 1
- JIJNOXBMFZYGTO-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(benzylamino)-1-(2-oxopropyl)purin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(CC(=O)C)C=1NCC1=CC=CC=C1 JIJNOXBMFZYGTO-UHFFFAOYSA-N 0.000 description 1
- JIBONTLFMNFVDB-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-(furan-2-ylmethylamino)-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1=CC=CO1 JIBONTLFMNFVDB-UHFFFAOYSA-N 0.000 description 1
- DNPWFFCLVWFUJL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(2-chlorophenyl)ethenyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC=C1Cl DNPWFFCLVWFUJL-UHFFFAOYSA-N 0.000 description 1
- LNFILCMEQZJNPS-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(2-fluorophenyl)ethyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1F LNFILCMEQZJNPS-UHFFFAOYSA-N 0.000 description 1
- RTGKPSZLHNTBHY-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(3-chlorophenyl)ethenyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC(Cl)=C1 RTGKPSZLHNTBHY-UHFFFAOYSA-N 0.000 description 1
- YOIKQMWUGNKVRV-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(3-chlorophenyl)ethyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC(Cl)=C1 YOIKQMWUGNKVRV-UHFFFAOYSA-N 0.000 description 1
- XJVCQLAUQKBJRX-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(3-fluorophenyl)ethenyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1C=CC1=CC=CC(F)=C1 XJVCQLAUQKBJRX-UHFFFAOYSA-N 0.000 description 1
- YOKWHIGQYYTNJF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(4-fluorophenyl)ethyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=C(F)C=C1 YOKWHIGQYYTNJF-UHFFFAOYSA-N 0.000 description 1
- MCUCPUKTSXQEQL-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[2-(furan-2-yl)ethyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CO1 MCUCPUKTSXQEQL-UHFFFAOYSA-N 0.000 description 1
- KJIHABVKCFKCTR-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-benzyl-2-[3-(furan-2-yl)propyl]-1-methylpurin-6-one Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCCC1=CC=CO1 KJIHABVKCFKCTR-UHFFFAOYSA-N 0.000 description 1
- NRHCAFORTDHCLF-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-1-methyl-2-(2-phenylethyl)purin-6-one Chemical compound CN1C(=O)C=2N(CC#CC)C(N3CC(N)CCC3)=NC=2N=C1CCC1=CC=CC=C1 NRHCAFORTDHCLF-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101100460776 Arabidopsis thaliana NPY2 gene Proteins 0.000 description 1
- 101100460788 Arabidopsis thaliana NPY5 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- QUWJMJLJXBZASG-UHFFFAOYSA-N C#CCN1C(=O)C2=C(N=C1NCC3=CC=CC=C3)N=C(N2CC4=CC=CC=C4)N5CCCC(C5)N Chemical compound C#CCN1C(=O)C2=C(N=C1NCC3=CC=CC=C3)N=C(N2CC4=CC=CC=C4)N5CCCC(C5)N QUWJMJLJXBZASG-UHFFFAOYSA-N 0.000 description 1
- LQDFIFKEAZAXRF-UHFFFAOYSA-N C(C1=CC=CC=C1)N(C(O)=NOC#N)C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)N(C(O)=NOC#N)C1=CC=CC=C1 LQDFIFKEAZAXRF-UHFFFAOYSA-N 0.000 description 1
- UEKSDOLTEOARRF-UHFFFAOYSA-N CC(C)(C)OC(=O)NC1CCCN(C1)C2=NC3=C(N2CC4=CC=CC=C4)C(=O)N(C(=N3)NCC5=CC=CC=C5)C Chemical compound CC(C)(C)OC(=O)NC1CCCN(C1)C2=NC3=C(N2CC4=CC=CC=C4)C(=O)N(C(=N3)NCC5=CC=CC=C5)C UEKSDOLTEOARRF-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- 102100030488 HEAT repeat-containing protein 6 Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 description 1
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229940077672 Ileal bile acid transport inhibitor Drugs 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- DNSNBOXTSISBRD-UHFFFAOYSA-N NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1CC1=CC=CC=C1)=O)CC#C)CCC1=CC=CC=C1 Chemical compound NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1CC1=CC=CC=C1)=O)CC#C)CCC1=CC=CC=C1 DNSNBOXTSISBRD-UHFFFAOYSA-N 0.000 description 1
- 101150111774 NPY5R gene Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- 101710204865 Tyrosine-protein phosphatase 1 Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- NROPZSSDCFKWGM-UHFFFAOYSA-N [1-(1,7-dibenzyl-2-methylsulfanyl-6-oxopurin-8-yl)piperidin-3-yl]carbamic acid Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CC=3C=CC=CC=3)C(SC)=NC=2N=C1N1CCCC(NC(O)=O)C1 NROPZSSDCFKWGM-UHFFFAOYSA-N 0.000 description 1
- AWCJLAYPFJYHEA-UHFFFAOYSA-N [1-(2-amino-7-benzyl-1-methyl-6-oxopurin-8-yl)piperidin-3-yl]carbamic acid Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N)=NC=2N=C1N1CCCC(NC(O)=O)C1 AWCJLAYPFJYHEA-UHFFFAOYSA-N 0.000 description 1
- ZPOZZMARMIBGRF-UHFFFAOYSA-N [1-(7-benzyl-1-methyl-6-oxo-2-piperidin-1-ylpurin-8-yl)piperidin-3-yl]carbamic acid Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(N3CCCCC3)=NC=2N=C1N1CCCC(NC(O)=O)C1 ZPOZZMARMIBGRF-UHFFFAOYSA-N 0.000 description 1
- ZHCPBLIZNZSOEL-UHFFFAOYSA-N [1-(7-benzyl-2-benzylsulfanyl-1-methyl-6-oxopurin-8-yl)piperidin-3-yl]carbamic acid Chemical compound N=1C=2N=C(N3CC(CCC3)NC(O)=O)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1SCC1=CC=CC=C1 ZHCPBLIZNZSOEL-UHFFFAOYSA-N 0.000 description 1
- PSIBOKVYTMVKLM-UHFFFAOYSA-N [1-[7-benzyl-1-methyl-2-(methylamino)-6-oxopurin-8-yl]piperidin-3-yl]carbamic acid Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NC)=NC=2N=C1N1CCCC(NC(O)=O)C1 PSIBOKVYTMVKLM-UHFFFAOYSA-N 0.000 description 1
- KTZYOEKUNXZTLE-UHFFFAOYSA-N [1-[7-benzyl-2-(cyclohexylamino)-1-methyl-6-oxopurin-8-yl]piperidin-3-yl]carbamic acid Chemical compound N=1C=2N=C(N3CC(CCC3)NC(O)=O)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NC1CCCCC1 KTZYOEKUNXZTLE-UHFFFAOYSA-N 0.000 description 1
- RZCYJZBJHKWUEQ-UHFFFAOYSA-N [1-[7-benzyl-2-(cyclohexylmethylamino)-1-methyl-6-oxopurin-8-yl]piperidin-3-yl]carbamic acid Chemical compound N=1C=2N=C(N3CC(CCC3)NC(O)=O)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1NCC1CCCCC1 RZCYJZBJHKWUEQ-UHFFFAOYSA-N 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- HXELGNKCCDGMMN-UHFFFAOYSA-N [F].[Cl] Chemical compound [F].[Cl] HXELGNKCCDGMMN-UHFFFAOYSA-N 0.000 description 1
- JFYOIWRDTYVTEL-UHFFFAOYSA-N [K].C(N)(OC(C)(C)C)=O Chemical compound [K].C(N)(OC(C)(C)C)=O JFYOIWRDTYVTEL-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000005163 aryl sulfanyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229950010046 avasimibe Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
- 125000005171 cycloalkylsulfanyl group Chemical group 0.000 description 1
- AVKNGPAMCBSNSO-UHFFFAOYSA-N cyclohexylmethanamine Chemical compound NCC1CCCCC1 AVKNGPAMCBSNSO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- SLIKWVTWIGHFJE-UHFFFAOYSA-N diphenoxymethylidenecyanamide Chemical compound C=1C=CC=CC=1OC(=NC#N)OC1=CC=CC=C1 SLIKWVTWIGHFJE-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
- CNTUCYNHGOEVNY-UHFFFAOYSA-N ethyl 5-formamido-3-(3-methylbut-2-enyl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]imidazole-4-carboxylate Chemical compound CC(C)=CCN1C(C(=O)OCC)=C(NC=O)N=C1N1CC(NC(=O)OC(C)(C)C)CCC1 CNTUCYNHGOEVNY-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- FPEIMKAERNJXBH-UHFFFAOYSA-N ethyl formate;hydrochloride Chemical compound Cl.CCOC=O FPEIMKAERNJXBH-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- XNRUFCCSINPRKO-UHFFFAOYSA-N n-[2-[2-[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]ethyl]phenyl]methanesulfonamide Chemical compound N=1C=2N=C(N3CC(N)CCC3)N(CC=3C=CC=CC=3)C=2C(=O)N(C)C=1CCC1=CC=CC=C1NS(C)(=O)=O XNRUFCCSINPRKO-UHFFFAOYSA-N 0.000 description 1
- IBHZULCOLBZDGC-UHFFFAOYSA-N n-[2-[[8-(3-aminopiperidin-1-yl)-7-benzyl-1-methyl-6-oxopurin-2-yl]amino]ethyl]methanesulfonamide Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(NCCNS(C)(=O)=O)=NC=2N=C1N1CCCC(N)C1 IBHZULCOLBZDGC-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N p-hydroxybenzoic acid propyl ester Natural products CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- QCRMXSNNBRRWMR-UHFFFAOYSA-N tert-butyl N-[1-(7-benzyl-1,2-dimethyl-6-oxopurin-8-yl)piperidin-3-yl]carbamate Chemical compound CC1=NC2=C(C(=O)N1C)N(C(=N2)N3CCCC(C3)NC(=O)OC(C)(C)C)CC4=CC=CC=C4 QCRMXSNNBRRWMR-UHFFFAOYSA-N 0.000 description 1
- AVDIGJVYTMFEOU-UHFFFAOYSA-N tert-butyl N-[1-(7-benzyl-1-methyl-2-methylsulfanyl-6-oxopurin-8-yl)piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCN(C1)C2=NC3=C(N2CC4=CC=CC=C4)C(=O)N(C(=N3)SC)C AVDIGJVYTMFEOU-UHFFFAOYSA-N 0.000 description 1
- OSWLKUBQCXCVHX-UHFFFAOYSA-N tert-butyl N-[1-(7-benzyl-1-methyl-2-methylsulfinyl-6-oxopurin-8-yl)piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCN(C1)C2=NC3=C(N2CC4=CC=CC=C4)C(=O)N(C(=N3)S(=O)C)C OSWLKUBQCXCVHX-UHFFFAOYSA-N 0.000 description 1
- ZSWPNBVNIXQCOB-UHFFFAOYSA-N tert-butyl N-[1-(7-benzyl-1-methyl-2-methylsulfonyl-6-oxopurin-8-yl)piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1CC1=CC=CC=C1)=O)C)S(=O)(=O)C)=O ZSWPNBVNIXQCOB-UHFFFAOYSA-N 0.000 description 1
- POPCCAKPHCKRSJ-UHFFFAOYSA-N tert-butyl N-[1-(7-benzyl-1-methyl-6-oxopurin-8-yl)piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCN(C1)C2=NC3=C(N2CC4=CC=CC=C4)C(=O)N(C=N3)C POPCCAKPHCKRSJ-UHFFFAOYSA-N 0.000 description 1
- VOELTXXMOPEISP-UHFFFAOYSA-N tert-butyl N-[1-(7-benzyl-2-benzylsulfanyl-6-oxo-1H-purin-8-yl)piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(NC(C=2N1CC1=CC=CC=C1)=O)SCC1=CC=CC=C1)=O VOELTXXMOPEISP-UHFFFAOYSA-N 0.000 description 1
- JWABHDUKNBZAMB-UHFFFAOYSA-N tert-butyl N-[1-(7-benzyl-2-cyano-1-methyl-6-oxopurin-8-yl)piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(N(C(C2N1CC1=CC=CC=C1)=O)C)C#N)=O JWABHDUKNBZAMB-UHFFFAOYSA-N 0.000 description 1
- OXSLBCYWGJJDJU-UHFFFAOYSA-N tert-butyl N-[1-(7-benzyl-2-methylsulfanyl-6-oxo-1H-purin-8-yl)piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCN(C1)C2=NC3=C(N2CC4=CC=CC=C4)C(=O)NC(=N3)SC OXSLBCYWGJJDJU-UHFFFAOYSA-N 0.000 description 1
- DLAWTOCUWGGPMZ-UHFFFAOYSA-N tert-butyl N-[1-(7-benzyl-6-oxo-1-phenacylpurin-8-yl)piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=CN(C(C=2N1CC1=CC=CC=C1)=O)CC(C1=CC=CC=C1)=O)=O DLAWTOCUWGGPMZ-UHFFFAOYSA-N 0.000 description 1
- QOCWGAXLFOFHOT-UHFFFAOYSA-N tert-butyl N-[1-(7-benzyl-6-oxo-1H-purin-8-yl)piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCN(C1)C2=NC3=C(N2CC4=CC=CC=C4)C(=O)NC=N3 QOCWGAXLFOFHOT-UHFFFAOYSA-N 0.000 description 1
- OGJALFVZXPQFNX-UHFFFAOYSA-N tert-butyl N-[1-[1-[(4-methoxynaphthalen-1-yl)methyl]-7-(3-methylbut-2-enyl)-6-oxopurin-8-yl]piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=CN(C(C=2N1CC=C(C)C)=O)CC1=CC=C(C2=CC=CC=C12)OC)=O OGJALFVZXPQFNX-UHFFFAOYSA-N 0.000 description 1
- JYRTZLKQOOCMEI-UHFFFAOYSA-N tert-butyl N-[1-[1-benzyl-2-methyl-7-(3-methylbut-2-enyl)-6-oxopurin-8-yl]piperidin-3-yl]carbamate Chemical compound CC1=NC2=C(C(=O)N1CC3=CC=CC=C3)N(C(=N2)N4CCCC(C4)NC(=O)OC(C)(C)C)CC=C(C)C JYRTZLKQOOCMEI-UHFFFAOYSA-N 0.000 description 1
- JLADOFPUANBJHO-UHFFFAOYSA-N tert-butyl N-[1-[1-methyl-7-(3-methylbut-1-enyl)-2-methylsulfanyl-6-oxopurin-8-yl]piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1C=CC(C)C)=O)C)SC)=O JLADOFPUANBJHO-UHFFFAOYSA-N 0.000 description 1
- SCWRHWZTLTZWSQ-UHFFFAOYSA-N tert-butyl N-[1-[1-methyl-7-(3-methylbut-2-enyl)-6-oxo-2-(2-phenylethyl)purin-8-yl]piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1CC=C(C)C)=O)C)CCC1=CC=CC=C1)=O SCWRHWZTLTZWSQ-UHFFFAOYSA-N 0.000 description 1
- KBNPOQXXWWVYPF-UHFFFAOYSA-N tert-butyl N-[1-[2-methyl-7-(3-methylbut-2-enyl)-1-(naphthalen-1-ylmethyl)-6-oxopurin-8-yl]piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1CC=C(C)C)=O)CC1=CC=CC2=CC=CC=C12)C)=O KBNPOQXXWWVYPF-UHFFFAOYSA-N 0.000 description 1
- VFKLXKDPJOMWJV-UHFFFAOYSA-N tert-butyl N-[1-[7-benzyl-1-methyl-6-oxo-2-(2-phenylethylamino)purin-8-yl]piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1CC1=CC=CC=C1)=O)C)NCCC1=CC=CC=C1)=O VFKLXKDPJOMWJV-UHFFFAOYSA-N 0.000 description 1
- NTODDGRCXGTIHR-UHFFFAOYSA-N tert-butyl N-[1-[7-benzyl-1-methyl-6-oxo-2-(2-phenylethylsulfanyl)purin-8-yl]piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1CC1=CC=CC=C1)=O)C)SCCC1=CC=CC=C1)=O NTODDGRCXGTIHR-UHFFFAOYSA-N 0.000 description 1
- ORNVOVTUAKJKSL-UHFFFAOYSA-N tert-butyl N-[1-[7-benzyl-2-(dimethylamino)-1-methyl-6-oxopurin-8-yl]piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1CC1=CC=CC=C1)=O)C)N(C)C)=O ORNVOVTUAKJKSL-UHFFFAOYSA-N 0.000 description 1
- IEIZZLAQYHZJRE-UHFFFAOYSA-N tert-butyl N-[1-[7-benzyl-2-[(4-fluorophenyl)methylamino]-1-methyl-6-oxopurin-8-yl]piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1CC1=CC=CC=C1)=O)C)NCC1=CC=C(C=C1)F)=O IEIZZLAQYHZJRE-UHFFFAOYSA-N 0.000 description 1
- PNDMOKXSDJRXQJ-UHFFFAOYSA-N tert-butyl N-[1-[7-benzyl-2-methylsulfanyl-6-oxo-1-(2-phenylethyl)purin-8-yl]piperidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(CCC1)C1=NC=2N=C(N(C(C=2N1CC1=CC=CC=C1)=O)CCC1=CC=CC=C1)SC)=O PNDMOKXSDJRXQJ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FRHOQDDDDFBHGW-UHFFFAOYSA-N tert-butyl n-piperidin-1-ylcarbamate Chemical compound CC(C)(C)OC(=O)NN1CCCCC1 FRHOQDDDDFBHGW-UHFFFAOYSA-N 0.000 description 1
- KRRBFUJMQBDDPR-UHFFFAOYSA-N tetrabutylazanium;cyanide Chemical compound N#[C-].CCCC[N+](CCCC)(CCCC)CCCC KRRBFUJMQBDDPR-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
Claims (10)
- Dérivés de purine de la formule générale :
R1 représente un atome d'hydrogène,
un groupe alkyle en C1-8,
un groupe alcényle en C3-8,
un groupe alcényle en C3-4, qui est substitué par un groupe (alkyloxy en C1-2)carbonyle, aminocarbonyle, (alkyle en C1-3)aminocarbonyle, di(alkyle en C1-3)aminocarbonyle, pyrrolidin-1-ylcarbonyle, pipéridin-1-ylcarbonyle ou morpholin-4-ylcarbonyle,
un groupe alcynyle en C3-8,
un groupe alkyle en C1-6, substitué par un groupe Ra, où
Ra représente un groupe cycloalkyle en C3-7, hétéroaryle, cyano, carboxy, (alkyloxy en C1-3)carbonyle, aminocarbonyle, (alkyle en C1-3)aminocarbonyle, di(alkyle en C1-3)aminocarbonyle, pyrrolidin-1-ylcarbonyle, pipéridin-1-ylcarbonyle, morpholin-4-ylcarbonyle, pipérazin-1-ylcarbonyle, 4-méthylpipérazin-1-ylcarbonyle ou 4-éthylpipérazin-1-ylcarbonyle,
un groupe alkyle en C1-6 substitué par un groupe phényle, où le cycle phényle est substitué par les groupes R10 à R14 et
R10 représente un atome d'hydrogène,
un atome de fluor, de chlore, de brome ou d'iode,
un groupe alkyle en C1-4, hydroxy ou alkyloxy en C1-4,
un groupe nitro, amino, (alkyle en C1-3)amino, di(alkyle en C1-3)amino, cyano(alkyle en C1-3)amino, N-(cyano(alkyle en C1-3))-N-(alkyle en C1-3)amino, (alkyloxy en C1-3)carbonyl(alkyle en C1-3)amino, pyrrolidin-1-yle, pipéridin-1-yle, morpholin-4-yle, pipérazin-1-yle ou 4-(alkyle en C1-3)pipérazin-1-yle,
un groupe formylamino, (alkyle en C1-3)carbonylamino, (cycloalkyle en C3-6)carbonylamino, (cycloalkyle en C3-6)(alkyle en C1-3)carbonylamino, arylcarbonylamino, aryl(alkyle en C1-3)carbonylamino, (alkyloxy en C1-3)carbonylamino, aminocarbonylamino, (alkyle en C1-3)aminocarbonylamino, di(alkyle en C1-3)aminocarbonylamino, pyrrolidin-1-ylcarbonylamino, pipéridin-1-ylcarbonylamino, morpholin-4-ylcarbonylamino, pipérazin-1-ylcarbonylamino ou 4-(alkyle en C1-3)pipérazin-1-ylcarbonylamino, (alkyle en C1-3)sulfonylamino, bis(alkylsulfonyl en C1-3)amino, aminosulfonylamino, (alkyle en C1-3)aminosulfonylamino, di(alkyle en C1-3)aminosulfonylamino, pyrrolidin-1-ylsulfonylamino, pipéridin-1-ylsulfonylamino, morpholin-4-ylsulfonylamino, pipérazin-1-ylsulfonylamino ou 4-(alkyle en C1-3)pipérazin-1-ylsulfonylamino, (alkylamino en C1-3)thiocarbonylamino, ((alkyloxy en C1-3)carbonylamino)-carbonylamino, arylsulfonylamino ou aryl(alkyle en C1-3)sulfonylamino,
un groupe N-(alkyle en C1-3)formylamino, N-(alkyle en C1-3)-N-((alkyle en C1-3-carbonyl))amino, N-(alkyle en C1-3)-N-((cycloalkyle en C3-6)-carbonyl)amino, N-(alkyle en C1-3)-N-((cycloalkyle en C3-6)-(alkyle en C1-3)-carbonyl)amino, N-(alkyle en C1-3)-N-(arylcarbonyl)amino, N-(alkyle en C1-3)-N-((arylalkyle en C1-3)-carbonyl)amino, N-(alkyle en C1-3)-N-((alkyloxy en C1-3)-carbonyl)amino, N-(aminocarbonyl)-N-(alkyle en C1-3)amino, N-(alkyle en C1-3)-aminocarbonyl)-N-(alkyle en C1-3)amino, N-[di(alkyle en C1-3)aminocarbonyl]-N-(alkyle en C1-3)amino, N-(alkyle en C1-3)-N-((alkyle en C1-3)-sulfonyl)amino, N-(alkyle en C1-3)-N-(arylsulfonyl)amino ou N-(alkyle en C1-3)-N-(aryl-(alkyle en C1-3)-sulfonyl)amino,
un groupe 2-oxoimidazolidin-1-yle, 2,4-dioxoimidazolidin-1-yle, 2,5-dioxoimidazolidin-1-yle ou 2-oxohexahydropyrimidin-1-yle, dans lequel l'atome d'azote en position 3 peut être substitué chaque fois, par un groupe méthyle ou éthyle,
un groupe cyano, carboxy, (alkyloxy en C1-3)carbonyle, aminocarbonyle, (alkyle en C1-3)aminocarbonyle, di(alkyle en C1-3)aminocarbonyle, pyrrolidin-1-ylcarbonyle, pipéridin-1-ylcarbonyle, morpholin-4-ylcarbonyle, pipérazin-1-ylcarbonyle ou 4-(alkyle en C1-3)pipérazin-1-ylcarbonyle,
un groupe (alkyle en C1-3)carbonyle ou arylcarbonyle,
un groupe carboxy(alkyle en C1-3), (alkyloxy en C1-3)carbonyl(alkyle en C1-3), cyano(alkyle en C1-3), aminocarbonyl(alkyle en C1-3), (alkyle en C1-3)aminocarbonyl(alkyle en C1-3), di(alkyle en C1-3)aminocarbonyl(alkyle en C1-3), pyrrolidin-1-ylcarbonyl(alkyle en C1-3), pipéridin-1-ylcarbonyl(alkyle en C1-3), morpholin-4-ylcarbonyl(alkyle en C1-3), pipérazin-1-ylcarbonyl(alkyle en C1-3) ou 4-(alkyle en C1-3)pipérazin-1-ylcarbonyl(alkyle en C1-3),
un groupe carboxy(alkyloxy en C1-3), (alkyloxy en C1-3)carbonyl(alkyloxy en C1-3), cyano(alkyloxy en C1-3), aminocarbonyl(alkyloxy en C1-3), (alkyle en C1-3)aminocarbonyl(alkyloxy en C1-3), di(alkyle en C1-3)aminocarbonyl(alkyloxy en C1-3), pyrrolidin-1-ylcarbonyl(alkyloxy en C1-3), pipéridin-1-ylcarbonyl(alkyloxy en C1-3), morpholin-4-ylcarbonyl(alkyloxy en C1-3), pipérazin-1-ylcarbonyl(alkyloxy en C1-3) ou 4-(alkyle en C1-3)pipérazin-1-ylcarbonyl(alkyloxy en C1-3),
un groupe hydroxy(alkyle en C1-3), (alkyloxy en C1-3)(alkyle en C1-3), amino(alkyle en C1-3), (alkyle en C1-3)amino(alkyle en C1-3), di(alkyle en C1-3)amino(alkyle en C1-3), pyrrolidin-1-yl(alkyle en C1-3), pipéridin-1-yl(alkyle en C1-3), morpholin-4-yl(alkyle en C1-3), pipérazin-1-yl(alkyle en C1-3), 4-(alkyle en C1-3)pipérazin-1-yl(alkyle en C1-3), un groupe hydroxy(alkyloxy en C1-3), (alkyloxy en C1-3)(alkyloxy en C1-3), (alkyle en C1-3) sulfanyl (alkyloxy en C1-3), (alkyle en C1-3) sulfinyl(alkyloxy en C1-3), (alkyle en C1-3) sulfonyl(alkyloxy en C1-3), amino(alkyloxy en C1-3), (alkyle en C1-3)amino(alkyloxy en C1-3), di(alkyle en C1-3)amino(alkyloxy en C1-3), pyrrolidin-1-yl(alkyloxy en C1-3), pipéridin-1-yl(alkyloxy en C1-3), morpholin-4-yl(alkyloxy en C1-3), pipérazin-1-yl(alkyloxy en C1-3), 4-(alkyle en C1-3)pipérazin-1-yl(alkyloxy en C1-3),
un groupe mercapto, (alkyle en C1-3)sulfanyle, (alkyle en C1-3)sulfinyle, (alkyle en C1-3)sulfonyle, (alkyle en C1-3)sulfonyloxy, arylsulfonyloxy, trifluorométhylsulfanyle, trifluorométhylsulfinyle ou trifluorométhylsulfonyle,
un groupe sulfo, aminosulfonyle, (alkyle en C1-3)aminosulfonyle, di(alkyle en C1-3) aminosulfonyle, pyrrolidin-1-ylsulfonyle, pipéridin-1-ylsulfonyle, morpholin-4-ylsulfonyle, pipérazin-1-ylsulfonyle ou 4-(alkyle en C1-3)pipérazin-1-ylsulfonyle,
un groupe méthyle ou méthoxy substitué par 1 à 3 atomes de fluor,
un groupe éthyle ou éthoxy substitué par 1 à 5 atomes de fluor,
un groupe alcényle en C2-4 ou alcynyle en C2-4,
un groupe alcényloxy en C3-4 ou alcynyloxy en C3-4,
un groupe cycloalkyle en C3-6 ou cycloalkyloxy en C3-6,
un groupe (cycloalkyle en C3-6)-(alkyle en C1-3) ou (cycloalkyle en C3-6)-(alkyloxy en C1-3),
un groupe aryle, aryloxy, aryl(alkyle en C1-3) ou aryl(alkyloxy en C1-3),
R11 et R12, qui peuvent être identiques ou différents, représentent un atome d'hydrogène, un atome de fluor, de chlore, de brome ou d'iode, un groupe alkyle en C1-3, trifluorométhyle, hydroxy, alkyloxy en C1-3 ou cyano, ou
R11 avec R12, dans la mesure ou ceux-ci sont liés à des atomes de carbone voisins, représentent également un groupe méthylènedioxy, difluorométhylènedioxy ou alkylène en C3-5 linéaire, et
R13 et R14, qui peuvent être identiques ou différents, représentent un atome d'hydrogène, un atome de fluor, de chlore ou de brome, un groupe trifluorométhyle, alkyle en C1-3, ou alkyloxy en C1-3,
un groupe phényl(alkyle en C1-4), dans lequel la partie alkyle est substituée par un groupe cyano, carboxy, (alkyloxy en C1-3)carbonyle, aminocarbonyle, (alkyle en C1-3)aminocarbonyle, di(alkyle en C1-3)aminocarbonyle, pyrrolidin-1-ylcarbonyle, pipéridin-1-ylcarbonyle, morpholin-4-ylcarbonyle, et la partie phényle est substituée par les groupes R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe phényle substituée par les groupes R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe phényl(alcényle en C2-3), dans lequel la partie phényle est substituée par les groupes R10 R14 où R10 R14 sont définis comme indiqué ci-dessus,
un groupe phényl-(CH2)m-A-(CH2)n, dans lequel la partie phényle est substituée par les groupes R10 à R14 , où R10 à R14 sont définis comme indiqué ci-dessus, et
A représente un groupe carbonyle, m le nombre 0, 1 ou 2 et n le nombre 1, 2 ou 3,
un groupe phénylcarbonylméthyle, dans lequel la partie phényle est substituée par les groupes R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus, et la partie méthyle est substituée par un groupe alkyle en C1-3,
un groupe phényl-(CH2)m-B-(CH2)n, dans lequel la partie phényle est substituée par les groupes R10 à R14, où R10 à R14, m et n sont définis comme indiqué ci-dessus, et
B représente un groupe méthylène, qui est substitué par un groupe hydroxy, alkyloxy en C1-3, amino, (alkyle en C1-3)amino, di(alkyle en C1-3)amino, mercapto, (alkyle en C1-3)sulfanyle, (alkyle en C1-3)sulfinyle ou (alkyle en C1-3)sulfonyle, et le cas échéant, est substitué en outre, par un groupe méthyle ou éthyle,
un groupe naphtyl(alkyle en C1-3), dans lequel la partie naphtyle est substituée par les groupes R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe naphtyl-(CH2)m A-(CH2)n, dans lequel la partie phényle est substituée par les groupes R10 à R14, où R10 à R14, A, m et n sont définis comme indiqué ci-dessus,
un groupe naphtyl-(CH2)m-B-(CH2)n, dans lequel la partie phényle est substituée par les groupes R10 à R14, où R10 à R14, B, m et n sont définis comme indiqué ci-dessus,
un groupe [1,4]naphtoquinon-2-yle, chromèn-4-on-3-yle, 1-oxoindan-2-yle, 1,3-dioxoindan-2-yle ou 2,3-dihydro-3-oxobenzofuran-2-yle,
un groupe hétéroaryl-(CH2)m-A-(CH2)n, dans lequel A, m et n sont définis comme indiqué ci-dessus,
un groupe hétéroaryl-(CH2)m-B-(CH2)n, dans lequel B, m et n sont définis comme indiqué ci-dessus,
un groupe (alkyle en C1-6)-A-(CH2)n, dans lequel A et n sont définis comme indiqué ci-dessus,
un groupe (cycloalkyle en C3-7)-(CH2)m-A-(CH2)n, dans lequel A, m et n sont définis comme indiqué ci-dessus,
un groupe (cycloalkyle en C3-7)-(CH2)m-B-(CH2)n, dans lequel B, m et n sont définis comme indiqué ci-dessus,
un groupe R21-A-(CH2)n, dans lequel R21 représente un groupe (alkyloxy en C1-3)carbonyle, aminocarbonyle, (alkyle en C1-3)aminocarbonyle, di(alkyle en C1-3)aminocarbonyle, pyrrolidin-1-ylcarbonyle, pipéridin-1-ylcarbonyle ou morpholin-4-ylcarbonyle, pipérazin-1-ylcarbonyle, 4-méthylpipérazin-1-ylcarbonyle ou 4-éthylpipérazin-1-ylcarbonyle et A et n sont définis comme indiqué ci-dessus,
un groupe phényl-(CH2)m-D-(alkyle en C1-3), dans lequel la partie phényle est substituée par les groupes R10 à R14, où R10 à R14 et m sont définis comme indiqué ci-dessus, et D représente un atome d'oxygène ou de soufre, un groupe imino, (alkyle en C1-3)imino, sulfinyle ou sulfonyle,
un groupe naphtyl-(CH2)m-D-(alkyle en C1-3), dans lequel la partie naphtyle est substituée par les groupes R10 à R14, où R10 à R14, D et m sont définis comme indiqué ci-dessus,
un groupe alkyle en C2-6 substitué par un groupe Rb, où
Rb est isolé par au moins deux atomes de carbone de l'atome d'azote cyclique en position 1 du squelette purine, et
Rb représente un groupe hydroxy, alkyloxy en C1-3, mercapto, (alkyle en C1-3) sulfanyle, (alkyle en C1-3) sulfinyle, (alkyle en C1-3) sulfonyle, amino, (alkyle en C1-3)carbonylamino, (cycloalkyle en C3-6)carbonylamino, arylcarbonylamino, (alkyle en C1-3)amino, di(alkyle en C1-3)amino, pyrrolidin-1-yle, pipéridin-1-yle, morpholin-4-yle, pipérazin-1-yle ou 4-(alkyle en C1-3)pipérazin-1-yle,
un groupe cycloalkyle en C3-6, ou
un groupe amino ou arylcarbonylamino,
R2 représente un atome d'hydrogène,
un groupe alkyle en C1-8,
un groupe alcényle en C3-8,
un groupe alcényle en C3-4, qui est substitué par un groupe (alkyloxy en C1-2)-carbonyle, aminocarbonyle, (alkyle en C1-3)aminocarbonyle, di(alkyle en C1-3)-aminocarbonyle, pyrrolidin-1-ylcarbonyle, pipéridin-1-ylcarbonyle ou morpholin-4-ylcarbonyle,
un groupe alcynyle en C3-8,
un groupe cycloalkyle en C3-6,
un groupe alkyle en C1-6, substitué par un groupe Ra, où Ra est défini comme indiqué ci-dessus,
un groupe phényle, qui est substitué par R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe alkyle en C1-6 substitué par un groupe phényle, où le cycle phényle est substitué par les groupes R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe phényl(alkyle en C1-4), dans lequel la partie alkyle est substituée par un groupe cyano, carboxy, (alkyloxy en C1-3)carbonyle, aminocarbonyle, (alkyle en C1-3)aminocarbonyle, di(alkyle en C1-3)aminocarbonyle, pyrrolidin-1-ylcarbonyle, pipéridin-1-ylcarbonyle, morpholin-4-ylcarbonyle, et la partie phényle est substituée par les groupes R10 à R14, où R10 R14 sont définis comme indiqué ci-dessus,
un groupe phényl-(alcényl en C2-3), où la partie phényle est substituée par R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe hétéroaryle,
un groupe phényl-(CH2)m-A- ou phényl-(CH2)m-A-(CH2)n, dans lequel la partie phényle est respectivement substituée par les groupes R10 à R14 où A, R10, à R14, m et n sont définis comme indiqué ci-dessus,
un groupe phénylcarbonylméthyle dans lequel la partie phényle est respectivement substituée par R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus, et la partie méthyle est substituée par un groupe alkyle en C1-3,
un groupe phényl-(CH2)m-B- ou phényl-(CH2)m-B-(CH2)n, dans lequel la partie phényle est respectivement substituée par R10 à R14 où B, R10 à R14 m et n sont définis comme indiqué ci-dessus,
un groupe naphtyl(alkyle en C1-3), dans lequel la partie naphtyle est substituée par les groupes R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe naphtyl-(CH2)m-A- ou naphtyl-(CH2)m-A-(CH2)n, dans lequel la partie naphtyle est respectivement substituée par R10 à R14, où A, R10 à R14, m et n sont définis comme indiqué ci-dessus,
un groupe naphtyl-(CH2)m-B- ou naphtyl-(CH2)m-B-(CH2)n, dans lequel la partie naphtyle est respectivement substituée par R10 à R14, où R10 à R14, B, m et n sont définis comme indiqué ci-dessus,
un groupe hétéroaryl-(CH2)m-A- ou hétéroaryl-(CH2)m-A-(CH2)n, où A, m et n sont définis comme indiqué ci-dessus,
un groupe hétéroaryl-(CH2)m-B- ou hétéroaryl-(CH2)m-B-(CH2)n, où B, m et n sont définis comme indiqué ci-dessus,
un groupe (alkyle en C1-6)-A- ou (alkyle en C1-6)-A-(CH2)n, où A et n sont définis comme indiqué ci-dessus,
un groupe (cycloalkyle en C3-7)-(CH2)m-A- ou (cycloalkyle en C3-7)-(CH2)m-A-(CH2)n, où A, m et n sont définis comme indiqué ci-dessus,
un groupe (cycloalkyle en C3-7)-(CH2)m-B- ou (cycloalkyle en C3-7)-(CH2)m-B-(CH2)n, où B, m et n sont définis comme indiqué ci-dessus,
un groupe R21-A-(CH2)n, dans lequel R21, A et n sont définis comme indiqué ci-dessus,
un groupe phényl-(CH2)m-D-(alkyle en C1-3), dans lequel la partie phényle est substituée par les groupes R10 à R14, où R10 à R14, D et m sont définis comme indiqué ci-dessus,
un groupe naphtyl-(CH2)m-D-(alkyle en C1-3), dans lequel la partie naphtyle est substituée par les groupes R10 à R14, où R10 à R14 D et m sont définis comme indiqué ci-dessus,
un groupe alkyle en C1-6 substitué par un groupe Rb, où Rb est défini comme indiqué ci-dessus,
un groupe cyano, carboxy, (alkyloxy en C1-3)carbonyle, aminocarbonyle, (alkyle en C1-3)aminocarbonyle, di(alkyle en C1-3)aminocarbonyle, pyrrolidin-1-ylcarbonyle, pipéridin-1-ylcarbonyle, morpholin-4-ylcarbonyle, pipérazin-1-ylcarbonyle, 4-méthylpipérazin-1-ylcarbonyle ou 4-éthylpipérazin-1-ylcarbonyle,
un groupe amino, (alkyle en C1-6)amino ou di(alkyle en C1-6)amino,
un groupe amino substitué par les radicaux R15 et R16, dans lequel
R15 représente un atome d'hydrogène ou un groupe alkyle en C1-6, et
R16 représente un groupe alkyle en C1-6, qui est substitué par Ra, où Ra est défini comme indiqué ci-dessus,
un groupe amino substitué par les radicaux R15 et R17, dans lequel
R15 est défini comme indiqué ci-dessus, et
R17 représente un groupe alkyle en C2-6, qui est substitué par un groupe hydroxy, alkyloxy en C1-3, aryloxy, mercapto, (alkyle en C1-3)sulfanyle, (alkyle en C1-3)sulfinyle, (alkyle en C1-3)sulfonyle, (alkyle en C1-3)sulfonylamino, arylsulfanyle, arylsulfinyle, arylsulfonyle, arylsulfonylamino, (alkyle en C1-3)carbonylamino, (cycloalkyle en C3-6)carbonylamino, arylcarbonylamino, (alkyle en C1-3) oxycarbonylamino, aminocarbonylamino, (alkyle en C1-3)aminocarbonylamino, di(alkyle en C1-3)aminocarbonylamino, amino, (alkyle en C1-3)amino, di(alkyle en C1-3)amino, pyrrolidin-1-yle, pipéridin-1-yle, morpholin-4-yle, pipérazin-1-yle, 4-(alkyle en C1-3)pipérazin-1-yle,
un groupe (cycloalkyle en C3-6)amino ou N-(cycloalkyle en C3-6)-N-(alkyle en C1-3)amino,
un groupe phénylamino ou N-(phényl)-N-(alkyle en C1-3)amino, dans lequel la partie phényle est respectivement substituée par R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe phényl(alkyle en C1-6)amino ou N-(phényl-(alkyle en C1-6))-N-(alkyle en C1-3)amino, dans lequel la partie phényle est respectivement substituée par R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe naphtylamino ou N-(naphtyl)-N-(alkyle en C1-3)amino,
un groupe naphtyl(alkyle en C1-6)amino ou N-(naphtyl-(alkyle en C1-6))-N-(alkyle en C1-3)amino,
un groupe hétéroarylamino ou N-(hétéroaryl)-N-(alkyle en C1-3)amino,
un groupe pyrrolidin-1-yle, pipéridin-1-yle, homopipéridin-1-yle, morpholin-4-yle, homomorpholin-4-yle, pipérazin-1-yle, 4-(alkyle en C1-3)pipérazin-1-yle, homopipérazin-1-yle ou 4-(alkyle en C1-3)homopipérazin-1-yle, ou
un groupe alkyloxy en C1-6, cycloalkyloxy en C3-6 ou (cycloalkyle en C3-6)-(alkyloxy en C1-6),
un groupe (alkyle en C1-6)sulfanyle, (cycloalkyle en C3-6)sulfanyle ou (cycloalkyle en C3-6)-(alkyle en C1-6)sulfanyle,
un groupe phényloxy ou phénylsulfanyle, dans lequel la partie phényle est respectivement substituée par R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe phényl(alkyloxy en C1-6) ou phényl-(alkyle en C1-6)sulfanyle, dans lequel la partie phényle est respectivement substituée par R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe naphtyloxy ou naphtylsulfanyle, dans lequel la partie naphtyle est respectivement substituée par R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe naphtyl-(alkyloxy en C1-6) ou naphtyl-(alkyle en C1-6)sulfanyle, dans lequel la partie naphtyle est respectivement substituée par R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
un groupe hétéroaryloxy ou hétéroarylsulfanyle, ou
un groupe hétéroaryl-(alkyloxy en C1-6) ou hétéroaryl-(alkyle en C1-6)sulfanyle,
R3 représente un groupe alkyle en C1-8,
un groupe alkyle en C1-4 substitué par un groupe Rc, où
Rc représente un groupe cycloalkyle en C3-7 le cas échéant substitué par un ou deux groupes alkyle en C1-3,
un groupe cycloalcényle en C5-7 le cas échéant substitué par un ou deux groupes alkyle en C1-3,
un groupe aryle, ou
un groupe furanyle, thiényle, oxazolyle, isoxazolyle, thiazolyle, isothiazolyle, pyridyle, pyridazinyle, pyrimidyle ou pyrazinyle, où les radicaux hétérocycliques indiqués ci-dessus peuvent être substitués chaque fois, par un ou deux groupes alkyle en C1-3, ou par un atome de fluor, de chlore, de brome ou d'iode ou par un groupe trifluorométhyle, cyano ou alcoxy en C1-3,
un groupe alcényle en C3-8,
un groupe alcényle en C3-6, substitué par un atome de fluor, de chlore ou de brome ou un groupe trifluorométhyle,
un groupe alcynyle en C3-8,
un groupe aryle, ou
un groupe aryl-(alcényle en C2-4),
et
R4 représente un groupe azétidin-1-yle ou pyrrolidin-1-yle, qui est substitué en position 3 par un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino, et peut être substitué en outre, par un ou deux groupes alkyle en C1-3,
un groupe pipéridin-1-yle ou hexahydroazépin-1-yle, qui est substitué en position 3 ou 4 par un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino, et peut être substitué en outre, par un ou deux groupes alkyle en C1-3,
un groupe 3-aminopipéridin-1-yle, dans lequel la partie pipéridin-1-yle est substituée en outre, par un groupe aminocarbonyle, (alkyle en C1-2)aminocarbonyle, di(alkyle en C1-2)aminocarbonyle, pyrrolidin-1-ylcarbonyle, (2-cyanopyrrolidin-1-yl)carbonyle, thiazolidin-3-ylcarbonyle, (4-cyanothiazolidin-3-yl)carbonyle, pipéridin-1-ylcarbonyle ou morpholin-4-ylcarbonyle,
un groupe 3-aminopipéridin-1-yle, dans lequel la partie pipéridin-1-yle est substituée en outre, en position 4 ou 5, par un groupe hydroxy ou méthoxy,
un groupe 3-aminopipéridin-1-yle, dans lequel le groupe méthylène en position 2 ou 6 est remplacé par un groupe carbonyle,
un groupe pipéridin-1-yle ou hexahydroazépin-1-yle, substitué en position 3 par un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino, dans lesquels chaque fois deux atomes d'hydrogène sur le squelette carboné du groupe pipéridin-1-yle ou hexahydroazépin-1-yle, sont remplacés par un pont alkylène linéaire, où ce pont contient 2 à 5 atomes de carbone, lorsque les deux atomes d'hydrogène se trouvent sur le même atome de carbone, ou contient 1 à 4 atomes de carbone lorsque les atomes d'hydrogène se trouvent sur des atomes de carbone voisins, ou contient 1 à 4 atomes de carbone lorsque les atomes d'hydrogène se trouvent sur des atomes de carbone, qui sont séparés par un atome, ou contient 1 à 3 atomes de carbone lorsque les deux atomes d'hydrogène se trouvent sur des atomes de carbone, qui sont séparés par deux atomes,
un groupe azétidin-1-yle, pyrrolidin-1-yle, pipéridin-1-yle ou hexahydroazépin-1-yle, qui est substitué par un groupe amino(alkyle en C1-3), (alkyle en C1-3)amino(alkyle en C1-3) ou di(alkyle en C1-3)amino(alkyle en C1-3),
un groupe pipérazin-1-yle ou [1,4]diazépan-1-yle, le cas échéant substitué sur le squelette carboné, par un ou deux groupes alkyle en C1-3,
un groupe 3-iminopipérazin-1-yle, 3-imino-[1,4]diazépan-1-yle ou 5-imino-[1,4]diazépan-1-yle, le cas échéant substitué sur le squelette carboné, par un ou deux groupes alkyle en C1-3,
un groupe [1,4]diazépan-1-yle, le cas échéant substitué par un ou deux groupes alkyle en C1-3, qui est substitué en position 6 par un groupe amino,
un groupe cycloalkyle en C3-7, qui est substitué par un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino,
un groupe cycloalkyle en C3-7, qui est substitué par un groupe amino(alkyle en C1-3), (alkyle en C1-3)amino(alkyle en C1-3) ou di(alkyle en C1-3)amino(alkyle en C1-3),
un groupe (cycloalkyle en C3-7)-(alkyle en C1-2), qui est substitué dans la partie cycloalkyle, par un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino,
un groupe (cycloalkyle en C3-7)-(alkyle en C1-2), qui est substitué dans la partie cycloalkyle, par un groupe amino(alkyle en C1-3), (alkyle en C1-3)amino(alkyle en C1-3) ou di(alkyle en C1-3)amino(alkyle en C1-3),
un groupe (cycloalkyle en C3-7)amino, qui est substitué dans la partie cycloalkyle, par un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino, où les deux atomes d'azote dans la partie cycloalkyle sont séparés l'un de l'autre, par au moins deux atomes de carbone,
un groupe N-(cycloalkyle en C3-7)-N-(alkyle en C1-3)amino, dans lequel la partie cycloalkyle est substituée par un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino, où les deux atomes d'azote dans la partie cycloalkyle sont séparés l'un de l'autre, par au moins deux atomes de carbone,
un groupe cyclo(alkyle en C3-7)amino, dans lequel la partie cycloalkyle est substituée par un groupe amino(alkyle en C1-3), (alkyle en C1-3)amino(alkyle en C1-3) ou di(alkyle en C1-3)amino(alkyle en C1-3),
un groupe N-(cycloalkyle en C3-7)-N-(alkyle en C1-3)amino, dans lequel la partie cycloalkyle est substituée par un groupe amino(alkyle en C1-3), (alkyle en C1-3)-amino(alkyle en C1-3) ou di(alkyle en C1-3)amino(alkyle en C1-3),
un groupe (cycloalkyle en C3-7)(alkyle en C1-2)amino, dans lequel la partie cycloalkyle est substituée par un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino,
un groupe N-((cycloalkyle en C3-7)-(alkyle en C1-2))-N-(alkyle en C1-2)amino, dans lequel la partie cycloalkyle est substituée par un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino,
un groupe (cycloalkyle en C3-7)(alkyle en C1-2)amino, dans lequel la partie cycloalkyle est substituée par un groupe amino(alkyle en C1-3), (alkyle en C1-3)-amino(alkyle en C1-3) ou di(alkyle en C1-3)amino(alkyle en C1-3),
un groupe N-((cycloalkyle en C3-7)-(alkyle en C1-2))-N-(alkyle en C1-2)amino, dans lequel la partie cycloalkyle est substituée par un groupe amino(alkyle en C1-3), (alkyle en C1-3)amino(alkyle en C1-3) ou di(alkyle en C1-3)amino(alkyle en C1-3),
un groupe R19-(alkyle en C2-4)amino, dans lequel R19 est séparé de l'atome d'azote de la partie (alkyle en C2-4)amino par au moins deux atomes de carbone, et
R19 représente un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino,
un groupe R19-(alkyle en C2-4)amino, dans lequel l'atome d'azote de la partie (alkyle en C2-4)amino, est substitué par un groupe alkyle en C1-3 et R19 est séparé de l'atome d'azote de la partie (alkyle en C2-4)amino par au moins deux atomes de carbone, où R19 est défini comme indiqué ci-dessus,
un groupe amino substitué par le radical R20, dans lequel
R20 représente un groupe azétidin-3-yle, azétidin-2-ylméthyle, azétidin-3-ylméthyle, pyrrolidin-3-yle, pyrrolidin-2-ylméthyle, pyrrolidin-3-ylméthyle, pipéridin-3-yle, pipéridin-4-yle, pipéridin-2-ylméthyle, pipéridin-3-ylméthyle ou pipéridin-4-ylméthyle, où les radicaux mentionnés pour R20 peuvent être substitués chaque fois, par un ou deux groupes alkyle en C1-3,
un groupe amino substitué par le radical R20 et un groupe alkyle en C1-3, dans lequel R20 est défini comme indiqué ci-dessus, où les radicaux mentionnés pour R20 peuvent être substitués chaque fois, par un ou deux groupes alkyle en C1-3,
un groupe R19-(alkyle en C3-4), dans lequel la partie alkyle en C3-4 est linéaire et peut être en outre, substitué par un ou deux groupes alkyle en C1-3, où R19 est défini comme indiqué ci-dessus,
un groupe 3-amino-2-oxopipéridin-5-yle ou 3-amino-2-oxo-1-méthylpipéridin-5-yle, un groupe pyrrolidin-3-yle, pipéridin-3-yle, pipéridin-4-yle, hexahydroazépin-3-yle ou hexahydroazépin-4-yle, qui est substitué en position 1 par un groupe amino, (alkyle en C1-3)amino ou di(alkyle en C1-3)amino,
ou un groupe azétidin-2-yl-(alkyle en C1-2), azétidin-3-yl-(alkyle en C1-2), pyrrolidin-2-yl-(alkyle en C1-2), pyrrolidin-3-yle, pyrrolidin-3-yl-(alkyle en C1-2), pipéridin-2-yl-(alkyle en C1-2), pipéridin-3-yle, pipéridin-3-yl-(alkyle en C1-2), pipéridin-4-yle ou pipéridin-4-yl-(alkyle en C1-2), où les groupes cités précédemment peuvent être substitués chaque fois, par un ou deux groupes alkyle en C1-3,
où par groupes aryle mentionnés lors de la définition des radicaux cités ci-dessus, on entend des groupes phényle ou naphtyle, qui peuvent être mono- ou disubstitués indépendamment l'un de l'autre, par Rh, où les substituants peuvent être identiques ou différents, et Rh représente un atome de fluor, de chlore, de brome ou d'iode, un groupe trifluorométhyle, cyano, nitro, amino, aminocarbonyl, aminosulfonyle, méthylsulfonyle, acétylamino, méthylsulfonylamino, alkyle en C1-3, cyclopropyle, éthényle, éthynyle, hydroxy, alcoxy en C1-3, difluorométhoxy ou trifluorométhoxy, par groupes hétéroaryle mentionnés lors de la définition des radicaux cités ci-dessus, on entend un groupe pyrrolyle, furannyle, thiényle, pyridyle, indolyle, benzofurannyle, benzothiophényle, quinoléinyle ou isoquinoléinyle,
ou un groupe pyrrolyle, furannyle, thiényle ou pyridyle, dans lequel un ou deux groupes méthine sont remplacés par un atome d'azote,
ou un groupe indolyle, benzofurannyle, benzothiophényle, quinoléinyle ou isoquinoléinyle, dans lequel un à trois groupes méthine sont remplacés par un atome d'azote,
ou un groupe 1,2-dihydro-2-oxopyridinyle, 1,4-dihydro-4-oxopyridinyle, 2,3-dihydro-3-oxopyridazinyle, 1,2,3,6-tétrahydro-3,6-dioxopyridazinyle, 1,2-dihydro-2-oxopyrimidinyle, 3,4-dihydro-4-oxopyrimidinyle, 1,2,3,4-tétrahydro-2,4-dioxopyrimidinyle, 1,2-dihydro-2-oxopyrazinyle, 1,2,3,4-tétrahydro-2,3-dioxopyrazinyle, 2,3-dihydro-2-oxoindolyle, 2,3-dihydrobenzofurannyle, 2,3-dihydro-2-oxo-1H-benzimidazolyle, 2,3-dihydro-2-oxo-benzoxazolyle, 1,2-dihydro-2-oxoquinoléinyle, 1,4-dihydro-4-oxoquinoléinyle, 1,2-dihydro-1-oxoisoquinoléinyle, 1,4-dihydro-4-oxocinnolinyle, 1,2-dihydro-2-oxoquinazolinyle, 3,4-dihydro-4-oxoquinazolinyle, 1,2,3,4-tétrahydro-2,4-dioxoquinazolinyle, 1,2-dihydro-2-oxoquinoxalinyle, 1,2,3,4-tétrahydro-2,3-dioxoquinoxalinyle, 1,2-dihydro-1-oxophtalazinyle, 1,2,3,4-tétrahydro-1,4-dioxophtalazinyle, chromanyle, coumarinyle, 2,3-dihydrobenzo-[1,4]dioxinyle ou 3,4-dihydro-3-oxo-2H-benzo[1,4]oxazinyle,
où les groupes hétéroaryle indiqués ci-dessus peuvent être substitués par R10 à R14, où R10 à R14 sont définis comme indiqué ci-dessus,
où sauf indication contraire, les groupes alkyle, alcényle et alcynyle indiqués ci-dessus peuvent être linéaires ou ramifiés,
ainsi que les dérivés N-oxydés ou méthylés ou éthylés sur l'atome d'azote cyclique en position 3 ou 9 du squelette hypoxanthine,
ainsi que les dérivés, dans lesquels le groupe 6-oxo du squelette hypoxanthine est remplacé par un groupe thioxo,
avec la condition que les composés
8-(pipéridin-4-ylméthyl)-7-(4-fluorobenzyl)-1,7-dihydropurin-6-one,
8-(1-méthylpipéridin-4-ylméthyl)-7-(4-fluorobenzyl)-1,7-dihydropurin-6-one,
8-(pipéridin-4-ylamino)-7-(4-fluorobenzyl)-1,7-dihydropurin-6-one, et
8-(1-méthylpipéridin-4-ylamino)-7-(4-fluorobenzyl)-1,7-dihydropurin-6-one, sont exclus,
leurs tautomères, énantiomères, diastéréoisomères, leurs mélanges et leurs sels. - Dérivés de purine de la formule générale I selon la revendication 1,
dans laquelle R1, R2 et R3 sont définis comme indiqué à la revendication 1, et
R4 représente un groupe pyrrolidin-1-yle, qui est substitué en position 3 par un groupe amino,
un groupe pipéridin-1-yle, qui est substitué en position 3 par un groupe amino,
un groupe pipéridin-3-yle ou pipéridin-4-yle,
un groupe hexahydroazépin-1-yle, qui est substitué en position 3 ou 4 par un groupe amino,
un groupe pipérazin-1-yle ou [1,4]diazépan-1-yle,
un groupe (2-aminocyclohexyl)amino,
un groupe cyclohexyle, qui est substitué en position 3 par un groupe amino, ou
un groupe N-(2-aminoéthyl)méthylamino ou N-(2-aminoéthyl)éthylamino,
leurs tautomères, énantiomères, diastéréoisomères, leurs mélanges et leurs sels. - Dérivés de purine de la formule générale I selon la revendication 1, dans laquelle
R1 représente un atome d'hydrogène,
un groupe alkyle en C1-6,
un groupe alcényle en C3-6,
un groupe alcynyle en C3-4,
un groupe (cycloalkyle en C3-6)méthyle,
un groupe phényl-(alkyle en C1-3), dans lequel la partie phényle est substituée par R10 et R11, où
R10 représente un atome d'hydrogène, un atome de fluor, de chlore ou de brome, un groupe méthyle ou trifluorométhyle,
un groupe cyano, aminocarbonyle, diméthylaminocarbonyle ou méthylsulfonyle,
un groupe amino, acétylamino ou méthylsulfonylamino,
un groupe hydroxy, méthoxy, difluorométhoxy, trifluorométhoxy, carboxyméthoxy, méthoxycarbonylméthoxy, éthoxycarbonylméthoxy, aminocarbonylméthoxy, méthylaminocarbonylméthoxy, éthylaminocarbonylméthoxy ou diméthylaminocarbonylméthoxy, et
R11 représente un atome d'hydrogène, un atome de fluor ou de chlore, ou
un groupe méthyle ou méthoxy,
un groupe naphtylméthyle, dans lequel la partie naphtyle est substituée par R10 et R11, où R10 et R11 sont définis comme indiqué ci-dessus,
un groupe hétéroarylméthyle, où par le terme
hétéroaryle, on entend un groupe furannyle, thiényle, oxazolyle, isoxazolyle, thiazolyle, pyridyle, pyrimidinyle, pyrazinyle, quinoléinyle, isoquinoléinyle ou quinazolinyle et les groupes hétéroaryle indiqués ci-dessus sont substitués par R10 et R11, où R10 et R11 sont définis comme indiqué ci-dessus,
un groupe phénylcarbonylméthyle, dans lequel la partie phényle est substituée par R10 et R11, où R10 et R11 sont définis comme indiqué ci-dessus,
un groupe furanylcarbonylméthyle, thiénylcarbonylméthyle ou pyridylcarbonylméthyle,
ou un groupe 2-oxopropyle ou cyclohexylcarbonylméthyle,
R2 représente un atome d'hydrogène,
un groupe alkyle en C1-6,
un groupe alcényle en C3-6,
un groupe alcynyle en C3-4,
un groupe cycloalkyle en C3-6 ou (cycloalkyle en C3-6)alkyle en C1-3,
un groupe phényle, qui est substitué par R10 et R11, où R10 et R11 sont définis comme indiqué ci-dessus,
un groupe phényl-(alkyle en C1-3), dans lequel la partie phényle est substituée par R10 et R11, où R10 et R11 sont définis comme indiqué ci-dessus,
un groupe phényl-(alcényle en C2-3), dans lequel la partie phényle est substituée par R10 et R11, où R10 et R11 sont définis comme indiqué ci-dessus,
un groupe phénylcarbonylméthyle, dans lequel la partie phényle est substituée par R10 et R11, où R10 et R11 sont définis comme indiqué ci-dessus,
un groupe furannyle, thiényle ou pyridyle,
un groupe furannyl-(alkyle en C1-3), thiényl-(alkyle en C1-3), ou pyridyl-(alkyle en C1-3),
un groupe cyano,
un groupe amino, (alkyle en C1-4)amino ou di(alkyle en C1-4)amino,
un groupe amino substitué par les radicaux R15 et R16, dans lequel
R15 représente un atome d'hydrogène ou un groupe méthyle ou éthyle, et
R16 représente un groupe alkyle en C1-4, qui est substitué par un groupe cyano, carboxy, méthoxycarbonyle, éthyloxycarbonyle, aminocarbonyle, méthylaminocarbonyle, diméthylaminocarbonyle, éthylaminocarbonyle, diéthylaminocarbonyle, pyrrolidin-1-ylcarbonyle ou morpholin-4-ylcarbonyle,
un groupe amino substitué par les radicaux R15 et R17, dans lequel
R15 est défini comme indiqué ci-dessus, et
R17 représente un groupe alkyle en C2-4 linéaire, qui est substitué chaque fois à son extrémité, par un groupe amino, méthylamino, diméthylamino, acétylamino, éthyloxycarbonylamino, phénylcarbonylamino, méthylsulfonylamino, phénylsulfonylamino, hydroxy, méthoxy, phényloxy, méthylsulfanyle ou phénylsulfanyle,
un groupe pyrrolidin-1-yle, pipéridin-1-yle, morpholin-4-yle, pipérazin-1-yle ou 4-méthylpipérazin-1-yle,
un groupe (cycloalkyle en C3-6)amino ou (cycloalkyle en C3-6)(alkyle en C1-3)amino,
un groupe phénylamino,
un groupe phényl(alkyle en C1-3)amino, dans lequel la partie phényle est substituée par R10 et R11, où R10 et R11 sont définis comme indiqué ci-dessus,
un groupe naphtylméthylamino,
un groupe (hétéroaryl)(alkyle en C1-2)amino, où le terme hétéroaryle est défini comme indiqué ci-dessus, ou
un groupe méthylsulfanyle, benzylsulfanyle ou (2-phényléthyl)sulfanyle,
R3 représente un groupe alcényle en C4-6,
un groupe alcényle en C3-4, substitué par un atome de fluor, de chlore ou de brome ou un groupe trifluorométhyle,
un groupe 2-butyn-1-yle, ou
un groupe méthyle substitué par le groupe Rc, où
Rc représente un groupe 1-cyclopentèn-1-yle ou 1-cyclohexèn-1-yle,
un groupe phényle le cas échéant substitué par un atome de fluor, de chlore, de brome ou d'iode, par un groupe méthyle, trifluorométhyle, cyano, méthoxy, difluorométhoxy ou trifluorométhoxy,
un groupe phényle, qui est substitué par deux atomes de fluor,
un groupe naphtyle, ou
un groupe furanyle, thiényle ou pyridyle,
et
R4 représente un groupe pipéridin-1-yle, qui est substitué en position 3 par un groupe amino,
un groupe hexahydroazépin-1-yle, qui est substitué en position 3 ou 4 par un groupe amino,
un groupe (2-aminocyclohexyl)amino,
un groupe cyclohexyle, qui est substitué en position 3 par un groupe amino, ou
un groupe N-(2-aminoéthyl)méthylamino ou N-(2-aminoéthyl)éthylamino,
où sauf indication contraire, les groupes alkyle, alcényle et alcynyle mentionnés précédemment peuvent être linéaires ou ramifiés,
leurs tautomères, énantiomères, diastéréoisomères, leurs mélanges et leurs sels. - Dérivés de purine de la formule générale I selon la revendication 3, dans laquelle
R1 représente un atome d'hydrogène,
un groupe méthyle, benzyle ou 2-phényléthyle,
un groupe naphtylméthyle ou méthoxynaphtylméthyle, ou
un groupe phénylcarbonylméthyle,
R2 représente un atome d'hydrogène,
un groupe méthyle ou 2-phényléthyle,
un groupe phénylcarbonylméthyle,
un groupe cyano,
un groupe amino, méthylamino, diméthylamino, isopropylamino, cyclohexylamino, ou (cyclohexylméthyl)amino,
un groupe benzylamino, fluorobenzylamino ou (2-phényléthyl)amino, ou
un groupe pipéridin-1-yle,
R3 représente un groupe benzyle ou 3-méthylbut-2-èn-1-yle,
et
R4 représente un groupe 3-aminopipéridin-1-yle,
leurs tautomères, énantiomères, diastéréoisomères, leurs mélanges et leurs sels. - Composés suivants de la formule générale I selon la revendication 1 :(1) 8-(3-aminopipéridin-1-yl)-7-benzyl-2-benzylamino-1-méthyl-1,7-dihydropurin-6-one,(2) 8-(3-aminopipéridin-1-yl)-7-benzyl-2-(4-fluorobenzylamino)-1-méthyl-1,7-dihydropurin-6-one,(3) 8-(3-aminopipéridin-1-yl)-7-benzyl-1-méthyl-2[(2-phényléthyl)amino]-1,7-dihydropurin-6-one,(4) 8-(3-aminopipéridin-1-yl)-7-benzyl-2-isopropylamino-1-méthyl-1,7-dihydro-purin-6-one,(5) 8-(3-aminopipéridin-1-yl)-7-benzyl-1-méthyl-2-méthylamino-1,7-dihydropurin-6-one,(6) 8-(3-aminopipéridin-1-yl)-7-benzyl-2-cyclohexylamino-1-méthyl-1,7-dihydro-purin-6-one,(7) 8-(3-aminopipéridin-1-yl)-7-benzyl-2-[(cyclohexylméthyl)amino]-1-méthyl-1,7-dihydropurin-6-one,(8) 8-(3-aminopipéridin-1-yl)-7-benzyl-1-méthyl-2(pipéridin-1-yl)-1,7-dihydro-purin-6-one,(9) 8-(3-aminopipéridin-1-yl)-7-benzyl-2-diméthylamino-1-méthyl-1,7-dihydro-purin-6-one,(10) 2-amino-8-(3-aminopipéridin-1-yl)-7-benzyl-1-méthyl-1,7-dihydropurin-6-one,(11) 8-(3-aminopipéridin-1-yl)-2-benzylamino-1-méthyl-7-(3-méthylbut-2-èn-1-yl)-1,7-dihydropurin-6-one,(12) 8-(3-aminopipéridin-1-yl)-7-benzyl-1-méthyl-2-méthyl-1,7-dihydropurin-6-one,(13) 8-(3-aminopipéridin-1-yl)-1-méthyl-7-(3-méthylbut-2-èn-1-yl)-2-(2-phényléthyl)-1,7-dihydropurin-6-one,(14) 8-(3-aminopipéridin-1-yl)-7-benzyl-1-méthyl-1,7-dihydropurin-6-one,(15) 8-(3-aminopipéridin-1-yl)-7-benzyl-1-(2-oxo-2-phényléthyl)-1,7-dihydropurin-6-one,(16) 8-(3-aminopipéridin-1-yl)-2-méthyl-7-(3-méthylbut-2-èn-1-yl)-1-[(naphtalèn-1-yl)méthyl]-1,7-dihydropurin-6-one,(17) 8-(3-aminopipéridin-1-yl)-7-(3-méthylbut-2-èn-1-yl)-1-[(naphtalèn-1-yl) méthyl]-1,7-dihydropurin-6-one,(18) 8-(3-aminopipéridin-1-yl)-7-(3-méthylbut-2-èn-1-yl)-1-[(4-méthoxynaphtalèn-1-yl)méthyl]-1,7-dihydropurin-6-one,ainsi que leurs tautomères, énantiomères, diastéréoisomères, leurs mélanges et leurs sels.
- Sels physiologiquement compatibles des composés selon au moins une des revendications 1 à 5 avec des acides ou bases inorganiques ou organiques.
- Médicament, contenant un composé selon au moins une des revendications 1 à 5 ou un sel physiologiquement compatible selon la revendication 6, avec le cas échéant, un ou plusieurs supports et/ou agents de dilution inertes.
- Utilisation d'un composé selon au moins une des revendications 1 à 6, pour la préparation d'un médicament adapté au traitement du diabète de type I et de type II, l'arthrite, d'adipose, la transplantation d'allogreffe et l'ostéoporose engendrée par la calcitonine.
- Procédé de préparation d'un médicament selon la revendication 7, caractérisé en ce que l'on incorpore par une voie non chimique, un composé selon au moins une des revendications 1 à 6 dans un ou plusieurs supports et/ou agents de dilution inertes.
- Procédé de préparation de composés de la formule générale I selon les revendications 1 à 6, caractérisé en ce quea) pour la préparation de composés de la formule générale I, dans laquelle R4 représente un des groupes indiqués à la revendication 1, qui contiennent un groupe imino, amino, alkylamino ou dialkylamino,dans laquelle R1, R2 et R3 sont définis comme indiqué à la revendication 1 et
on déprotège un composé de la formule générale :
R4' représente un des groupes indiqués pour R4 à la revendication 1, qui contiennent un groupe imino, amino ou alkylamino, où le groupe imino, amino et respectivement, alkylamino est substitué par un groupe protecteur, comme par exemple t-butyloxycarbonyle, 2,2,2-trichloroéthoxycarbonyle ou carbobenzyloxycarbonyle, et ensuite, on alkyle le cas échéant,
et si souhaité, ensuite, on clive un groupe protecteur utilisé pendant les réactions pour la protection de groupes réactifs, et/ou
un composé ainsi obtenu de la formule générale I est séparé de ses stéréoisomères et/ou
un composé ainsi obtenu de la formule générale I est transformé en ses sels, en particulier pour l'utilisation pharmaceutique, en ses sels physiologiquement compatibles avec un acide inorganique ou organique.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10238477 | 2002-08-22 | ||
DE10238477A DE10238477A1 (de) | 2002-08-22 | 2002-08-22 | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
PCT/EP2003/009100 WO2004018469A1 (fr) | 2002-08-22 | 2003-08-16 | Nouveaux derives de purine, leur procede de production et leur utilisation en tant que medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1532150A1 EP1532150A1 (fr) | 2005-05-25 |
EP1532150B1 true EP1532150B1 (fr) | 2008-06-11 |
Family
ID=31197237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03792343A Expired - Lifetime EP1532150B1 (fr) | 2002-08-22 | 2003-08-16 | Nouveaux derives de purine, leur procede de production et leur utilisation en tant que medicament |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1532150B1 (fr) |
JP (1) | JP2006502144A (fr) |
AT (1) | ATE398128T1 (fr) |
AU (1) | AU2003258621A1 (fr) |
CA (1) | CA2496211A1 (fr) |
DE (2) | DE10238477A1 (fr) |
ES (1) | ES2308017T3 (fr) |
WO (1) | WO2004018469A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011055391A1 (fr) * | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Composés pyrimidine fusionnés substitués, leur préparation et leurs utilisations |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE10254304A1 (de) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
JP4887139B2 (ja) * | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
JPWO2004096806A1 (ja) * | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 縮合イミダゾール誘導体 |
DE602004026289D1 (de) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
WO2006058064A2 (fr) * | 2004-11-29 | 2006-06-01 | Merck & Co., Inc. | Aminopiperidines fusionnees utilisees comme inhibiteurs de la dipeptidyle peptidase-iv permettant de traiter ou de prevenir le diabete |
ATE481969T1 (de) * | 2004-10-01 | 2010-10-15 | Merck Sharp & Dohme | Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
JP5075125B2 (ja) * | 2005-08-26 | 2012-11-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療又は予防用ジペプチジルペプチダーゼiv阻害剤としての縮合アミノピペリジン |
NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
AU2006326564B2 (en) * | 2005-12-14 | 2011-06-23 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
WO2007112347A1 (fr) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyl peptidase |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
CL2007001011A1 (es) | 2006-04-11 | 2008-05-16 | Arena Pharm Inc | Metodo para la identificacion de secretagogos de gip, polipeptido inhibidor gastrico; y uso de un receptor acoplado a proteina g para clasificar compuestos de prueba como secretagogos de gip. |
EA030606B1 (ru) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы приготовления лекарственного средства, содержащего полиморфы |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP1852108A1 (fr) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Compositions d'inhibiteurs de la DPP IV |
WO2008055945A1 (fr) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2008065141A1 (fr) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Nouveaux inhibiteurs de glutaminylcyclase |
JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2146210A1 (fr) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY |
WO2009143477A1 (fr) * | 2008-05-22 | 2009-11-26 | Amgen Inc. | Hétérocycles en tant qu'inhibiteurs de protéine kinase |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
EA031225B1 (ru) | 2008-08-15 | 2018-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Ингибиторы дпп-4 для заживления ран |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sglt2阻害剤、dpp−iv阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
JP2012517977A (ja) | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害剤(リナグリプチン)を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
PT2482812T (pt) | 2009-10-02 | 2023-01-24 | Boehringer Ingelheim Int | Composições farmacêuticas compreendendo bi-1356 e metformina |
ES2760917T3 (es) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
JP6034781B2 (ja) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
NZ602809A (en) | 2010-05-05 | 2015-02-27 | Boehringer Ingelheim Int | Pharmaceutical formulations comprising pioglitazone and linagliptin |
EA201991014A1 (ru) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение диабета |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
WO2012123563A1 (fr) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012170702A1 (fr) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
WO2013006526A2 (fr) | 2011-07-05 | 2013-01-10 | Merck Sharp & Dohme Corp. | Hétérocycles tricycliques utiles comme inhibiteurs de la dipeptidyl peptidase-iv |
MX366629B (es) | 2011-07-15 | 2019-07-17 | Boehringer Ingelheim Int | Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas. |
WO2013055910A1 (fr) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
CN103130819B (zh) * | 2011-12-01 | 2016-01-20 | 中国科学院上海药物研究所 | 噻吩[3,2-d]并嘧啶-4-酮类化合物、其制备方法、药物组合物及用途 |
US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sirs及び/又は敗血症の治療に用いるdpp−4阻害薬としてのキサンチン誘導体 |
EP3685839A1 (fr) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein |
WO2013174767A1 (fr) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires |
JP6374862B2 (ja) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ladaの治療に使用するためのdpp−4阻害剤としてのキサンチン誘導体 |
WO2014045266A1 (fr) | 2012-09-24 | 2014-03-27 | Ulf Eriksson | Traitement de diabète de type 2 et d'états apparentés |
WO2014074668A1 (fr) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulateurs de gpr119 et traitement de troubles associés à ceux-ci |
CN110075098A (zh) | 2013-03-15 | 2019-08-02 | 勃林格殷格翰国际有限公司 | 利格列汀在心脏和肾脏保护性抗糖尿病治疗中的用途 |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
JP2019517542A (ja) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | リナグリプチンおよびメトホルミンの組合せ |
WO2018104263A1 (fr) | 2016-12-06 | 2018-06-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés d'amélioration de l'activité de médicaments à base d'incrétine chez des sujets en ayant besoin |
CA3058806A1 (fr) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Agoniste de ppar.gamma. pour le traitement de la paralysie supranucleaire progressive |
EP3461819B1 (fr) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibiteurs de la glutaminyl-cyclase |
US10561655B2 (en) * | 2018-03-21 | 2020-02-18 | Synblia Therapeutics, Inc. | SHP2 inhibitors and uses thereof |
WO2024091863A1 (fr) | 2022-10-25 | 2024-05-02 | Starrock Pharma Llc | Polythérapies combinatoires et rotationnelles pour l'obésité et d'autres maladies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8515934D0 (en) * | 1985-06-24 | 1985-07-24 | Janssen Pharmaceutica Nv | (4-piperidinomethyl and-hetero)purines |
ATE242775T1 (de) * | 1998-01-05 | 2003-06-15 | Eisai Co Ltd | Purinderivate und antagonisten des adenosin-a2- rezeptors, welche zur vorsorge oder heilung von diabetes dienen |
HUP0301622A3 (en) * | 2000-07-04 | 2006-05-29 | Novo Nordisk As | Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them |
-
2002
- 2002-08-22 DE DE10238477A patent/DE10238477A1/de not_active Withdrawn
-
2003
- 2003-08-16 JP JP2004530172A patent/JP2006502144A/ja active Pending
- 2003-08-16 ES ES03792343T patent/ES2308017T3/es not_active Expired - Lifetime
- 2003-08-16 CA CA002496211A patent/CA2496211A1/fr not_active Abandoned
- 2003-08-16 AT AT03792343T patent/ATE398128T1/de active
- 2003-08-16 EP EP03792343A patent/EP1532150B1/fr not_active Expired - Lifetime
- 2003-08-16 AU AU2003258621A patent/AU2003258621A1/en not_active Abandoned
- 2003-08-16 WO PCT/EP2003/009100 patent/WO2004018469A1/fr active IP Right Grant
- 2003-08-16 DE DE50309979T patent/DE50309979D1/de not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011055391A1 (fr) * | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Composés pyrimidine fusionnés substitués, leur préparation et leurs utilisations |
US8796290B2 (en) | 2009-11-09 | 2014-08-05 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
DE10238477A1 (de) | 2004-03-04 |
WO2004018469A1 (fr) | 2004-03-04 |
ES2308017T3 (es) | 2008-12-01 |
AU2003258621A1 (en) | 2004-03-11 |
DE50309979D1 (de) | 2008-07-24 |
EP1532150A1 (fr) | 2005-05-25 |
ATE398128T1 (de) | 2008-07-15 |
CA2496211A1 (fr) | 2004-03-04 |
JP2006502144A (ja) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1532150B1 (fr) | Nouveaux derives de purine, leur procede de production et leur utilisation en tant que medicament | |
EP1554278B1 (fr) | Derives de xanthine, leur production et leur utilisation comme medicaments | |
EP1709049B1 (fr) | Composes imidazol bicycliques, leur fabrication et leur utilisation comme medicaments | |
EP1689748B1 (fr) | Nouvelle xanthine 8-(piperazine-1-yl) et 8-( 1,4 diazepan-1-yl), sa production et son utilisation comme medicament | |
EP1758905B1 (fr) | 8-[3-amino-piperidine-1-yl]-xanthines, leur fabrication et leur utilisation comme inhibiteur de dpp-iv | |
EP1720875B1 (fr) | 8-[ 3-amino-piperidin-1-yl]-xanthines, leur production et leur utilisation comme medicament | |
EP1797093B1 (fr) | Nouvelles 3-methyl-7-butinyl-xanthines, leur production et leur utilisation comme medicaments | |
EP1761517B1 (fr) | Nouveaux imidazoles et triazoles, procede pour les produire et leur utilisation en tant que medicaments | |
EP1641799B1 (fr) | Derives d'imidazopyridazinones et d'imidazopyridones, leur preparation et leur utilisation comme medicaments | |
US7569574B2 (en) | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions | |
EP1791844A1 (fr) | 8-(3-amino-piperidin-1-yl)-7-(but-2-inyl)-xanthines, leur production et leur utilisation en tant que medicaments | |
DE10254304A1 (de) | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel | |
DE10359098A1 (de) | Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel | |
EP2228375A1 (fr) | Nouveaux dérivés de xanthine, leur fabrication et leur utilisation en tant que médicament | |
DE102004008112A1 (de) | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel | |
WO2005087774A1 (fr) | Imidazopyridazindione, sa fabrication et son utilisation comme medicament | |
DE102004012921A1 (de) | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel | |
DE102004017739A1 (de) | Neue 2-Amino-imidazo(4,5-d)pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel | |
DE102004032263A1 (de) | 8-[3-Amino-piperidin-1yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050322 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
17Q | First examination report despatched |
Effective date: 20050614 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 50309979 Country of ref document: DE Date of ref document: 20080724 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2308017 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080911 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081111 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080831 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080911 |
|
26N | No opposition filed |
Effective date: 20090312 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080816 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080611 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080912 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20140821 Year of fee payment: 12 Ref country code: CH Payment date: 20140820 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20140826 Year of fee payment: 12 Ref country code: AT Payment date: 20140619 Year of fee payment: 12 Ref country code: FR Payment date: 20140821 Year of fee payment: 12 Ref country code: GB Payment date: 20140820 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20140827 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 50309979 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 398128 Country of ref document: AT Kind code of ref document: T Effective date: 20150816 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20150816 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150816 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150816 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20160429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160301 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150816 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20160927 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150817 |